BioRestorative Therapies (BRTX) 10-Q 13 Nov 19 2019 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2019	Nov. 11, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	BioRestorative Therapies, Inc.
Entity Central Index Key	0001505497
Document Type	10-Q
Document Period End Date	Sep. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,761,527
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current Assets:
Cash	$ 98,113	$ 117,523
Accounts receivable	38,000	29,000
Prepaid expenses and other current assets	64,741	34,464
Total Current Assets	200,854	180,987
Property and equipment, net	105,619	175,235
Intangible assets, net	757,888	814,059
Security deposit	22,100	22,100
Deferred offering costs	371,725
Total Assets	1,458,186	1,192,381
Current Liabilities:
Accounts payable	1,743,596	1,893,827
Accrued expenses and other current liabilities	2,625,423	2,302,176
Accrued interest	628,976	338,619
Current portion of notes payable, net of debt discount of $733,886 and $936,866 at September 30, 2019 and December 31, 2018, respectively	7,526,128	3,625,659
Derivative liabilities	1,191,108	1,094,607
Total Current Liabilities	13,715,231	9,254,888
Accrued expenses, non-current portion		36,500
Accrued interest, non-current portion	14,345	18,137
Notes payable, non-current portion, net of debt discount of $78,919 and $75,497 at September 30, 2019 and December 31, 2018, respectively	157,143	523,894
Total Liabilities	13,886,719	9,833,419
Commitments and contingencies (See Note 6)
Stockholders' Deficiency:
Preferred stock, $0.01 par value; Authorized, 20,000,000 shares; None issued and outstanding at September 30, 2019 and December 31, 2018
Common stock, $0.001 par value; Authorized, 300,000,000 shares; Issued and outstanding 23,717,754 and 11,728,394 shares at September 30, 2019 and December 31, 2018, respectively	23,717	11,728
Additional paid-in capital	64,567,341	55,269,490
Accumulated deficit	(77,019,591)	(63,922,256)
Total Stockholders' Deficiency	(12,428,533)	(8,641,038)
Total Liabilities and Stockholders' Deficiency	$ 1,458,186	$ 1,192,381

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Notes payable current, debt discount	$ 733,886	$ 936,866
Notes payable non-current, debt discount	$ 78,919	$ 75,497
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	23,717,754	11,728,394
Common stock, shares outstanding	23,717,754	11,728,394

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Revenues	$ 38,000	$ 26,000	$ 98,000	$ 82,000
Operating Expenses:
Marketing and promotion	156,179	155,161	280,865	213,715
Consulting	373,975	417,601	1,507,582	1,268,485
Research and development	409,815	357,436	1,306,544	1,137,381
General and administrative	917,027	284,472	3,279,145	2,932,162
Total Operating Expenses	1,856,996	1,214,670	6,374,136	5,551,743
Loss From Operations	(1,818,996)	(1,188,670)	(6,276,136)	(5,469,743)
Other Expense:
Interest expense	(394,816)	(257,298)	(1,039,727)	(648,940)
Amortization of debt discount	(1,487,501)	(540,488)	(3,221,904)	(1,884,116)
Loss on extinguishment of notes payable, net	(1,290,623)	(320,383)	(2,291,218)	(384,171)
Change in fair value of derivative liabilities	(65,037)	(615,322)	(268,350)	(557,274)
Warrant modification expense		(3,100)		(3,100)
Total Other Expense	(3,237,977)	(1,736,591)	(6,821,199)	(3,477,601)
Net Loss	$ (5,056,973)	$ (2,925,261)	$ (13,097,335)	$ (8,947,344)
Net Loss Per Share
- Basic and Diluted	$ (0.23)	$ (0.39)	$ (0.74)	$ (1.32)
Weighted Average Number of Common Shares Outstanding
- Basic and Diluted	21,520,371	7,410,350	17,601,908	6,796,761

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Common Stock [Member]
Balance	$ 19,793	$ 6,747	$ 11,728	$ 6,112
Balance, shares	19,793,477	6,747,501	11,728,394	6,112,473
Shares and warrants issued for cash		$ 60	$ 2,191	$ 70
Shares and warrants issued for cash, shares		60,000	2,191,111	70,000
Exercise of warrant for purchase of common stock				$ 207
Exercise of warrant for purchase of common stock, shares				207,084
Shares and warrants issued in satisfaction of accrued consulting services				$ 19
Shares and warrants issued in satisfaction of accrued consulting services, shares				19,000
Conversion of notes payable and accrued interest into common stock		$ 70		$ 97
Conversion of notes payable and accrued interest into common stock, shares		70,406		97,424
Shares and warrants issued in exchange for notes payable and accrued interest				$ 2,107
Shares and warrants issued in exchange for notes payable and accrued interest, shares				2,106,525
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		$ 23	$ 79	$ 74
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions, shares		23,333	78,873	74,333
Warrant modifications
Beneficial conversion features related to convertible notes payable
Reclassification of derivative liabilities to equity
Stock-based compensation: common stock		$ 35	$ 75	$ 35
Stock-based compensation: common stock, shares		35,000	75,000	35,000
Stock-based compensation: options and warrants
Shares issued in exchange for notes payable and accrued interest	$ 3,924	$ 1,786	$ 9,634
Shares issued in exchange for notes payable and accrued interest, shares	3,924,277	1,785,599	9,634,376
Shares issued in satisfaction of accrued consulting services			$ 10
Shares issued in satisfaction of accrued consulting services, shares			10,000
Stock-based compensation: options
Net loss
Balance	$ 23,717	$ 8,721	$ 23,717	$ 8,721
Balance, shares	23,717,754	8,721,839	23,717,754	8,721,839
Additional Paid-In Capital [Member]
Balance	$ 63,000,354	$ 47,551,776	$ 55,269,490	$ 44,561,773
Shares and warrants issued for cash		74,940	254,120	99,930
Exercise of warrant for purchase of common stock				413,961
Shares and warrants issued in satisfaction of accrued consulting services				37,981
Conversion of notes payable and accrued interest into common stock		57,662		110,539
Shares and warrants issued in exchange for notes payable and accrued interest				4,338,074
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		33,973	61,141	121,379
Warrant modifications		3,100		3,100
Beneficial conversion features related to convertible notes payable		47,876		69,394
Reclassification of derivative liabilities to equity	171,569	105,187	2,809,565	105,187
Stock-based compensation: common stock		52,465	29,925	52,465
Stock-based compensation: options and warrants		(218,853)		1,491,146
Shares issued in exchange for notes payable and accrued interest	1,161,373	3,696,803	4,729,383
Shares issued in satisfaction of accrued consulting services			7,190
Stock-based compensation: options	234,045		1,406,527
Net loss
Balance	64,567,341	51,404,929	64,567,341	51,404,929
Accumulated Deficit [Member]
Balance	(71,962,618)	(57,426,536)	(63,922,256)	(51,404,453)
Shares and warrants issued for cash
Exercise of warrant for purchase of common stock
Shares and warrants issued in satisfaction of accrued consulting services
Conversion of notes payable and accrued interest into common stock
Shares and warrants issued in exchange for notes payable and accrued interest
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions
Warrant modifications
Beneficial conversion features related to convertible notes payable
Reclassification of derivative liabilities to equity
Stock-based compensation: common stock
Stock-based compensation: options and warrants
Shares issued in exchange for notes payable and accrued interest
Shares issued in satisfaction of accrued consulting services
Stock-based compensation: options
Net loss	(5,056,973)	(2,925,261)	(13,097,335)	(8,947,344)
Balance	(77,019,591)	(60,351,797)	(77,019,591)	(60,351,797)
Balance	(8,942,471)	(9,868,013)	(8,641,038)	(6,836,568)
Shares and warrants issued for cash		75,000	256,311	100,000
Exercise of warrant for purchase of common stock				414,168
Shares and warrants issued in satisfaction of accrued consulting services				38,000
Conversion of notes payable and accrued interest into common stock		57,732		110,636
Shares and warrants issued in exchange for notes payable and accrued interest				4,340,181
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions		33,996	61,220	121,453
Warrant modifications		3,100		3,100
Beneficial conversion features related to convertible notes payable		47,876		69,394
Reclassification of derivative liabilities to equity	171,569	105,187	2,809,565	105,187
Stock-based compensation: common stock		52,500	30,000	52,500
Stock-based compensation: options and warrants		(218,853)		1,491,146
Shares issued in exchange for notes payable and accrued interest	1,165,297	3,698,589	4,739,017
Shares issued in satisfaction of accrued consulting services			7,200
Stock-based compensation: options	234,045		1,406,527
Net loss	(5,056,973)	(2,925,261)	(13,097,335)	(8,947,344)
Balance	$ (12,428,533)	$ (8,938,147)	$ (12,428,533)	$ (8,938,147)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash Flows From Operating Activities
Net loss	$ (13,097,335)	$ (8,947,344)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount	3,221,904	1,884,116
Accretion of interest expense	375,344	427,908
Depreciation and amortization	161,418	183,070
Stock-based compensation	1,492,527	1,579,046
Loss on extinguishment of note payables, net	2,291,218	384,171
Gain on settlement of payables	(29,300)
Change in fair value of derivative liabilities	268,350	557,274
Consulting services provided in exchange for notes payble		131,935
Warrant modification expense		3,100
Changes in operating assets and liabilities:
Accounts receivable	(9,000)	12,000
Prepaid expenses and other current assets	(30,277)	(20,637)
Accounts payable	(379,028)	(342,725)
Accrued interest, expenses and other current liabilities	626,436	596,544
Total adjustments	7,989,592	5,395,802
Net Cash Used In Operating Activities	(5,107,743)	(3,551,542)
Cash Flows From Investing Activities
Purchases of property and equipment	(35,631)	(12,869)
Net Cash Used In Investing Activities	(35,631)	(12,869)
Cash Flows From Financing Activities
Offering costs incurred	(14,428)
Proceeds from notes payable	8,332,727	3,062,217
Repayments of notes payable - principal	(3,536,605)	(351,571)
Repayments of notes payable - prepayment premiums	(813,730)	(81,709)
Advances from officers and a family member of an officer		38,500
Repayments of advances from officers and a family member of an officer		(38,500)
Proceeds from exercise of warrants		414,168
Sales of common stock and warrants for cash	1,156,000	175,000
Net Cash Provided By Financing Activities	5,123,964	3,218,105
Net Decrease In Cash	(19,410)	(346,306)
Cash at beginning of period	117,523	451,680
Cash at end of period	98,113	105,374
Supplemental Disclosures of Cash Flow Information:
Interest	232,693	21,625
Income tax
Non-cash investing and financing activities:
Warrant modifications		3,100
Shares issued and recorded as debt discount in connection with notes payable issuances or extensions	61,220	121,453
Shares issued in exchange for notes payable and accrued interest	4,739,017	4,340,181
Conversion of notes payable and accrued interest into common stock		110,636
Shares and warrants issued in satisfaction of accrued consulting services	7,200	38,000
Bifurcated embedded conversion options and warrants recorded as derivative liability and debt discount	3,680,226	1,938,759
Beneficial conversion features recorded as debt discount		69,394
Reclassification of derivative liabilities to equity	2,809,565	105,187
Warrants issued for consulting services recorded as derivative liabilities	56,000
Accrued interest reclassified to notes payable principal	23,013
Offering costs in accounts payable and accrued expenses	357,297
Original issue discount in connection with notes payable	547,348	309,729
Consulting services provided in exchange for notes payable		$ 131,935

Business Organization and Natur

Business Organization and Nature of Operations	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Organization and Nature of Operations	Note 1 – Business Organization and Nature of Operations BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company” (See Note 3 – Summary of Significant Accounting Policies – Principles of Consolidation). BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT’s website is at www.biorestorative.com BRTX-100 The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information. Accordingly, they do not include all of the information and disclosures required by GAAP for annual financial statements. In the opinion of management, such statements include all adjustments (consisting only of normal recurring items) which are considered necessary for a fair presentation of the unaudited condensed consolidated financial statements of the Company as of September 30, 2019 and for the three and nine months ended September 30, 2019 and 2018. The results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the operating results for the full year ending December 31, 2019 or any other period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related disclosures of the Company as of December 31, 2018 and for the year then ended, which were filed with the Securities and Exchange Commission on Form 10-K on March 29, 2019.

Going Concern and Management's

Going Concern and Management's Plans	9 Months Ended
	Sep. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern and Management's Plans	Note 2 – Going Concern and Management’s Plans As of September 30, 2019, the Company had a working capital deficiency and a stockholders’ deficiency of $13,514,377 and $12,428,533, respectively. During the three and nine months ended September 30, 2019, the Company incurred net losses of $5,056,973 and $13,097,335, respectively. These conditions indicate that there is substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the filing date of this report. The Company’s primary source of operating funds since inception has been equity and debt financings. The Company intends to continue to raise additional capital through debt and equity financings. There is no assurance that these funds will be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such additional financing on a timely basis or, notwithstanding any request the Company may make, the Company’s debt holders do not agree to convert their notes into equity or extend the maturity dates of their notes, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate. The accompanying unaudited condensed consolidated financial statements have been prepared in conformity with U.S. GAAP, which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The unaudited condensed consolidated financial statements do not include any adjustment that might result from the outcome of this uncertainty. Subsequent to September 30, 2019, the Company has received aggregate equity financings and debt proceeds of $500,000 and $1,363,625, respectively, debt (inclusive of accrued interest) of $250,571 has been exchanged for common stock, $1,412,202 of debt (inclusive of accrued interest) has been repaid, and the due date for the repayment of $91,539 of debt has been extended to July 2020. As a result, the Company expects to have the cash required to fund its operations through December 2019 while it continues to apply efforts to raise additional capital, including through a contemplated public offering of its equity securities. While there can be no assurance that it will be successful, the Company is seeking to raise additional capital. As of the filing date of this report, the Company has notes payable with an aggregate principal balance of $593,400 which are past due. See Note 7 – Stockholders’ Deficiency and Note 9 – Subsequent Events for details. Between May 2019 and August 2019, holders of the Company’s notes in the aggregate principal amount of $1,565,000 entered into agreements with the Company pursuant to which the parties have agreed to exchange such notes for shares of the Company’s common stock and warrants in connection with the closing of the contemplated public offering. See Note 5 – Notes Payable – Related Party Notes; and – Convertible Notes.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates. Deferred Offering Costs Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with preparing for a contemplated public offering of the Company’s equity securities (as described in Note 7 – Stockholders’ Deficiency), are capitalized as non-current assets on the balance sheet. Upon a consummation of such contemplated offering (as to which no assurances can be given), the deferred offering costs will be offset against the equity offering proceeds. As of September 30, 2019, the Company incurred deferred offering costs in the amount of $371,725, of which $265,297 and $92,000 are included in accounts payable and accrued expenses, respectively, on the September 30, 2019 condensed consolidated balance sheet, in connection with such contemplated public offering. Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The five-step process outlined in the ASC 606 is as follows: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – When (or as) a performance obligation is satisfied, the Company shall recognize as revenue the amount of the transaction price that is allocated to the performance obligation. The contract terms are used to determine the transaction price. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – Revenue is recognized when (or as) goods or services are transferred to a customer. The Company satisfies each of its performance obligations by transferring control of the promised good or service underlying that performance obligation to the customer. Control is the ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. It includes the ability to prevent other entities from directing the use of, and obtaining the benefits from, an asset. Indicators that control has passed to the customer include: a present obligation to pay; physical possession of the asset; legal title; risks and rewards of ownership; and acceptance of the asset. Performance obligations can be satisfied at a point in time or over time. The Company recognizes all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012, as amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company recognizes sublicensing and royalty revenue on a per disc procedure basis when the third-party sale occurs. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three and nine months ended September 30, 2019, the Company recognized $38,000 and $98,000, respectively, of revenue related to the Company’s sublicenses. During the three and nine months ended September 30, 2018, the Company recognized $26,000 and $82,000, respectively, of revenue related to the Company’s sublicenses. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required. Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2019 2018 Options 4,909,618 3,588,451 Warrants 5,804,891 3,413,403 Convertible notes - common stock [1] 35,373,991 2,986,487 Convertible notes - warrants 2,776,450 - Total potentially dilutive shares 48,864,950 9,988,341 [1] As of September 30, 2019 and 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, on September 30, 2019 and September 30, 2018 there were 110,370,828 and 24,710,731 shares of common stock reserved for future note conversions, respectively. See Note 9 – Subsequent Events regarding the Board of Directors approval to increase the number of authorized shares of common stock, subject to shareholder approval. Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company estimates the fair value of the awards granted based on the market value of its freely tradable common stock as reported on the OTCQB market. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares. Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the unaudited condensed consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, the warrants, and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments. Sequencing Policy Under ASC 815-40-35 (“ASC 815”), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuances of securities to the Company’s employees and directors, or to compensate grantees in a share-based payment arrangement, are not subject to the sequencing policy. Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss. Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed. Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating these ASUs and their impact on its unaudited condensed consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The Company has adopted this standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and including interim periods within that fiscal year. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted this accounting standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In March 2019, the FASB issued ASU 2019-01, “Leases (Topic 842): Codification Improvements” (“Topic 842”) (“ASU 2019-01”). These amendments align the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. (Issue 1). The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all “principal payments received under leases” within investing activities. (Issue 2). Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. (Issue 3). The transition and effective date provisions apply to Issue 1 and Issue 2. They do not apply to Issue 3 because the amendments for that Issue are to the original transition requirements in Topic 842. This amendment will be effective for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating ASU 2019-01 and its impact on its unaudited condensed consolidated financial statements and financial statement disclosures. In July 2019, the FASB issued ASU 2019-07, “Codification Updates to SEC Sections — Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update)” (“ASU 2019-07”). ASU 2019-07 aligns the guidance in various SEC sections of the Codification with the requirements of certain SEC final rules. ASU 2019-07 is effective immediately. The adoption of ASU 2019-07 did not have a material impact on the Company’s unaudited condensed consolidated financial statements.

Accrued Expenses and Other Curr

Accrued Expenses and Other Current Liabilities	9 Months Ended
	Sep. 30, 2019
Accrued Liabilities and Other Liabilities [Abstract]
Accrued Expenses and Other Current Liabilities	Note 4 – Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities are comprised of the following: September 30, 2019 December 31, 2018 Accrued payroll and other accrued expenses $ 43,779 $ 91,560 Accrued research and development expenses 746,175 646,175 Accrued general and administrative expenses 1,320,104 1,084,831 Accrued director compensation 507,500 482,500 Deferred rent 7,865 33,610 Total accrued expenses 2,625,423 2,338,676 Less: accrued expenses, current portion 2,625,423 2,302,176 Accrued expenses, non-current portion $ - $ 36,500 During the nine months ended September 30, 2019, the Company entered into a settlement agreement with a certain consultant, pursuant to which $46,500 of previously accrued consulting fees were exchanged for 10,000 shares of the Company’s common stock and a $10,000 cash payment. The value of the shares was $7,200, and accordingly the Company recorded a gain on settlement of payables of $29,300 which is reflected within general and administrative expenses in the unaudited condensed consolidated statements of operations.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 5 – Notes Payable A summary of the notes payable activity during the nine months ended September 30, 2019 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2019 $ 720,000 $ 4,309,415 $ 132,501 $ (1,012,363 ) $ 4,149,553 Issuances 485,000 8,543,089 [1] - - 9,028,089 Exchanges for equity - (2,032,323 ) - 455,969 (1,576,354 ) Repayments (45,000 ) (3,484,105 ) (7,500 ) 428,939 (3,107,666 ) Extinguishment of notes payable - - (148,014 )[1] 6,196 (141,818 ) Recognition of debt discount - - - (4,288,794 ) (4,288,794 ) Accretion of interest expense - - - 375,344 375,344 Accrued interest reclassified to notes payable principal - - 23,013 - 23,013 Amortization of debt discount - - - 3,221,904 3,221,904 Outstanding, September 30, 2019 [2] $ 1,160,000 $ 7,336,076 [3] $ - $ (812,805 ) $ 7,683,271 [1] During the nine months ended September 30, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Convertible Notes - Conversions, Exchanges and Other for additional details. [2] As of September 30, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amounts of $450,000, $508,000 and $0, respectively, were considered past due (which excludes aggregate principal amounts of $25,000 and $150,000 of related party and convertible notes, respectively, which were extended to October 2019, effective as of September 30, 2019). See Note 9 – Subsequent Events for details regarding the repayment of certain past due notes payable. [3] As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $4,381,076 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $2,955,000, which are not currently convertible, will become convertible into shares of the Company’s common stock at the election of the respective holder subsequent to September 30, 2019. As of September 30, 2019, outstanding related party notes and convertible notes in the aggregate principal amounts of $1,150,000 and $990,000, respectively, provided for a mandatory conversion into common stock of the Company and warrants to purchase common stock of the Company in the same ratio upon the completion of an underwritten public offering by the Company. See Note 9 – Subsequent Events. Related Party Notes During the nine months ended September 30, 2019, the Company issued to family members of officers of the Company and a Scientific Advisory Board member (the “SAB Member”) notes payable in the aggregate principal amount of $485,000, which bear interest at the rate of 12% per annum and provide for original maturity dates between July 2019 and December 2019. During the nine months ended September 30, 2019, the Company partially repaid a certain related party note in the principal amount of $45,000. During the nine months ended September 30, 2019, the holders of certain related party notes in the aggregate principal amount of $505,000 entered into agreements with the Company pursuant to which the parties agreed that the maturity of the promissory notes held by such holders will be extended or further extended from dates from December 2018 and August 2019 to dates between July 2019 and December 2019. In consideration of the extensions, such notes in the aggregate principal amount of $475,000 provided for an exchange of such notes for an exchange of such notes for shares of common stock and warrants, as described below, in connection with a public offering of the Company’s securities (the “Public Offering”). The exchange price for the indebtedness will be equal to the lesser of (i) 75% of the public offering price of the common stock, or units of common stock and warrants, as the case may be, offered pursuant to the Public Offering or (ii) $0.60 per share (subject to adjustment for reverse stock splits and the like) (the “Exchange Price”). The number of shares of common stock issuable pursuant to the warrants to be issued to such holders will be equal to the number of shares of common stock issuable to them upon conversion of the principal amount of their respective notes. The exchange price of the warrants to be issued to such holders will be the lesser of (i) 125% of the Exchange Price or (ii) $0.80 per share (subject to adjustment for reverse stock splits and the like). Since the fair value of the new ECO exceeded 10% of the carrying amount of the debt, the note extensions were accounted for as extinguishments, and accordingly the Company recognized an aggregate net loss on extinguishment of $145,066 in connection with the derecognition of the net carrying amount of the extinguished debt of $510,887 (inclusive of $475,000 of principal and $35,887 of accrued interest) and the issuance of the new convertible notes in the same amount, plus the fair value of the new notes’ ECOs of an aggregate of $145,066. See Note 9 – Subsequent Events. In October 2019, the Company and a certain related party lender agreed to further extend the maturity date of a certain related party note with a principal balance of $25,000 from a maturity date in September 2019 to a new maturity date in October 2019, effective September 30, 2019. During the nine months ended September 30, 2019, the Company, a director of the Company, and a trust related to the director (the “Trust”) agreed that promissory notes held by the director and the Trust in the outstanding principal amounts of $175,000 and $500,000, respectively, will be exchanged for shares of common stock and warrants, as described below, in connection with the Public Offering. The exchange price for the indebtedness will be equal to 75% of the public offering price of the common stock, or units of common stock and warrants, as the case may be, offered pursuant to the Public Offering (the “Director/Trust Exchange Price”). The number of shares of common stock issuable pursuant to the warrants to be issued to the director and the Trust will be in the same ratio to the number of shares of common stock issued upon exchange of their indebtedness as the number of shares of common stock subject to any warrants included as part of units offered pursuant to the Public Offering (the “Public Warrants”) bears to the number of shares of common stock issued as part of the Public Offering units. The exercise price of the warrants to be issued to the director and the Trust will be 125% of the Director/Trust Exchange Price and the term of the warrants will be the same term as the Public Warrants. Concurrently with the exchange, the exercise prices of outstanding warrants held by the director and the Trust for the purchase of an aggregate of 1,377,842 shares of common stock of the Company will be reduced from between $1.50 and $4.00 per share to $0.75 per share and the expiration dates of such warrants will be extended from between December 2019 and March 2022 to December 2023. The exchange agreements were submitted for approval by the shareholders of the Company, which was obtained in August 2019. As of September 30, 2019, related party notes consisted of notes payable issued to certain directors of the Company, family members of officers of the Company, the SAB Member, and the Trust. A director and principal shareholder of the Company serves as a trustee of the Trust, which was established for the benefit of his immediate family. As of September 30, 2019, certain related party notes in the aggregate principal amount of $485,000 were convertible into shares of common stock of the Company at a conversion price of $0.60 per share, subject to adjustment, and a five year warrant (the “Warrant”) for the purchase of a number of shares equal to the number of shares issued upon the conversion of the principal amount of the note. The Warrant provides for an exercise price of $0.80 per share, subject to adjustment. Convertible Notes Issuances During the nine months ended September 30, 2019, the Company issued certain lenders convertible notes payable in the aggregate principal amount of $8,395,075 for aggregate cash proceeds of $7,847,727. The difference of $547,348 was recorded as a debt discount and will be amortized over the terms of the respective notes. The convertible notes bear interest at rates ranging between 8% to 15% per annum payable at maturity with original maturity dates ranging between July 2019 through September 2020. In connection with the issuance of a certain convertible note, the Company issued the lender 68,873 shares of the Company’s common stock and the relative fair value of $54,168 was recorded as debt discount and is being amortized over the term of the note. In connection with the issuance of certain convertible notes, the Company issued the lenders five-year warrants to purchase an aggregate of 295,000 shares of the Company’s common stock at exercise prices ranging from $0.45 per share to $1.00 per share. The aggregate grant date value of the warrants was $104,198, which was recorded as debt discount and is being amortized over the terms of the respective convertible notes. The warrants were subject to the Company’s sequencing policy and, as a result, were initially recorded as derivative liabilities. See below within this Note 5 – Notes Payable – Convertible Notes – Conversions, Exchanges and Other and Note 8 – Derivative Liabilities for additional details regarding the ECOs of the convertible notes. During the nine months ended September 30, 2019, a certain convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain other note payable in the same principal amount. See below within this Note 5 – Notes Payable – Convertible Notes – Conversions, Exchanges and Other for additional details. Embedded Conversion Options and Note Provisions As of September 30, 2019, outstanding convertible notes in the aggregate principal amount of $4,381,076 were convertible into shares of common stock of the Company as follows: (i) $2,355,076 of aggregate principal amount of convertible notes were convertible at a fixed price ranging from $0.25 to $2.00 per share for the first six months following the respective issue date, and thereafter at a conversion price generally equal to 58% of the fair value of the Company’s stock, subject to adjustment, until the respective note has been paid in full, (ii) 1,046,000 of aggregate principal amount of convertible notes were convertible generally at a range of 58% to 65% of the fair value of the Company’s stock, subject to adjustment, depending on the note, and (iii) $980,000 of aggregate principal amount of convertible notes were convertible into shares of common stock of the Company at a conversion price ranging from $0.50 to $0.60 per share, subject to adjustment, and five-year warrants to purchase common stock of the Company in the same ratio. The warrants provide for an exercise price ranging from $0.75 to $0.80 per share, subject to adjustment. Convertible notes in the aggregate principal amount of $990,000 provide for a mandatory conversion into common stock of the Company and warrants to purchase common stock of the Company in the same ratio upon the completion of an underwritten public offering by the Company of its securities whereby the conversion price shall be equal to the lower of the respective original conversion terms, or 75% of the offering price for the shares of common stock of the Company, or units of shares of common stock of the Company and warrants, as the case may be, sold pursuant to the public offering. The Company analyzes the ECOs of its convertible notes at issuance to determine whether the ECO should be bifurcated and accounted for as a derivative liability or if the ECO contains a beneficial conversion feature. See below within this Note 5 – Notes Payable – Convertible Notes – Embedded Conversion Options and Note Provisions and Note 8 – Derivative Liabilities for additional details regarding the ECOs of the convertible notes. Also see Note 9 – Subsequent Events. As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $2,955,000, which were not yet convertible, will become convertible into shares of the Company’s common stock subsequent to September 30, 2019 at a conversion price generally equal to 58% of the fair value of the Company’s stock, subject to adjustment, until the respective notes have been paid in full. As of September 30, 2019, outstanding convertible notes in the aggregate principal amount of $4,325,075 have prepayment premiums, whereby, in the event that the Company elects to prepay certain notes during the one hundred eighty-day period following the issue date, the respective holder is entitled to receive a prepayment premium of up to 35%, depending on the note, on the then outstanding principal balance including accrued interest. As of September 30, 2019, outstanding convertible notes in the aggregate principal amount of $4,252,688 have most favored nation (“MFN”) provisions, whereby, so long as such respective note is outstanding, upon any issuance by the Company of any security with certain identified provisions more favorable to the holder of such security, then at the respective holder’s option, those more favorable terms shall become a part of the transaction documents with the holder. As of September 30, 2019, notes with applicable MFN provisions were convertible using MFN conversion prices equal to 58% of the fair market value of the Company’s stock, as defined. During the nine months ended September 30, 2019, the Company determined that certain ECOs of issued or extended convertible notes were derivative liabilities. The aggregate issuance date value of the bifurcated ECOs was $3,990,135, of which $3,576,028 was recorded as a debt discount and is being amortized over the terms of the respective convertible notes and $414,108 was recognized as part of an extinguishment loss as described below. See Note 8 – Derivative Liabilities for additional details. Conversions, Exchanges and Other During the nine months ended September 30, 2019, the Company and certain lenders exchanged certain convertible notes with bifurcated ECOs with an aggregate net carrying amount of $4,255,838 (including an aggregate of $2,032,323 of principal less debt discount of $455,969, $122,111 of accrued interest and $2,557,373 related to the separated ECOs accounted for as derivative liabilities) for an aggregate of 9,634,376 shares of the Company’s common stock at conversion prices ranging from $0.11 to $0.43 per share. The common stock had an aggregate exchange date value of $4,739,017 and, as a result, the Company recorded a loss on extinguishment of notes payable of $483,179. See Note 8 – Derivative Liabilities for additional details. During the nine months ended September 30, 2019, the Company repaid an aggregate principal amount of $3,484,105 of convertible notes payable, $209,486 of the respective aggregate accrued interest and an aggregate of $813,730 of prepayment premiums. As a result of the repayments, the Company recorded a loss on extinguishment of notes payable of $1,242,669 and an aggregate of $428,939 of the related debt discounts were extinguished. During the nine months ended September 30, 2019, a certain lender to the Company acquired a promissory note (classified in Other Notes) issued by the Company in the outstanding amount of $148,014 (inclusive of accrued interest reclassified to principal of $23,013) from a certain lender to the Company. The Company exchanged the acquired note for a new convertible note in the principal amount of $148,014 which accrues interest at a rate of 12% per annum, payable on the maturity date in March 2020. The ECO of the note was subject to sequencing and the issuance date fair value of $84,798 was accounted for as a derivative liability (see Note 8 – Derivative Liabilities for additional details). Since the fair value of the new ECO exceeded 10% of the principal amount of the new note, the note exchange was accounted for as an extinguishment, and accordingly the Company recognized a net loss on extinguishment of $90,994 in connection with the derecognition of the net carrying amount of $141,818 of the extinguished debt and the issuance of the new convertible notes in the aggregate principal amount $148,014 plus the fair value of the new note’s ECO of an aggregate of $84,798. During the nine months ended September 30, 2019, the Company and certain lenders agreed to extend or further extend the maturity dates of certain convertible notes payable with an aggregate principal balance of $678,102 from maturity dates ranging from June 2019 to July 2019 to new maturity dates ranging from July 2019 to July 2020. In consideration of the extensions of certain convertible notes with an aggregate principal balance of $650,000, the Company modified the conversion terms of the lenders’ notes to provide for a mandatory conversion into common stock of the Company and a five-year warrant to purchase common stock of the Company in the same ratio upon the completion of an underwritten public offering by the Company of its securities, whereby, the conversion price shall be equal to the lower of the respective original conversion terms, or 75% of the offering price for the shares of common stock of the Company, or units of shares of common stock of the Company and warrants, as the case may be, sold pursuant to the public offering. Since the fair value of the new ECO exceeded 10% of the carrying amount of the debt, the note extensions were accounted for as extinguishments, and accordingly the Company recognized an aggregate net loss on extinguishment of $329,310 in connection with the derecognition of the net carrying amount of the extinguished debt of $702,387 (inclusive of $650,000 of principal and $52,387 of accrued interest) and the issuance of the new convertible notes in the same amount, plus the fair value of the new notes’ ECOs of an aggregate of $329,310. See Note 9 – Subsequent Events. In October 2019, the Company and certain lenders agreed to further extend the maturity dates of certain convertible notes payable with an aggregate principal balance of $150,000 from maturity dates in September 2019 to new maturity dates in October 2019, effective September 30, 2019. Other Notes Exchange and Other During the nine months ended September 30, 2019, the Company and a certain lender agreed to an extension of the maturity date of a certain note payable with a principal balance of $125,000 from a maturity date in January 2019 to a new maturity date in December 2019. In consideration of the extension, the Company issued the lender 10,000 shares of the Company’s common stock. The issuance date fair value of the common stock of $7,052 was recorded as debt discount and is being amortized over the remaining term of the note. During the nine months ended September 30, 2019, a convertible promissory note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain other note payable in the same principal amount. See above within Note 5 – Notes Payable – Convertible Notes – Conversions, Exchanges and Other for additional details. During the nine months ended September 30, 2019, the Company partially repaid a certain promissory note in the principal amount of $7,500.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 6 – Commitments and Contingencies Consulting Agreements Business Advisory Services In January 2019, an agreement for business advisory services that had expired on December 31, 2018 was further extended and now provides for an expiration date of December 31, 2019. In consideration of the extension of the term of the consulting agreement, the Company issued to the consultant a five-year, immediately vested warrant for the purchase of 100,000 shares of the Company’s common stock at an exercise price of $1.00 per share. The grant date value of the warrant of $56,000 was recognized immediately as stock-based compensation expense which is reflected as consulting expense in the unaudited condensed consolidated financial statements. The warrant was subject to the Company’s sequencing policy and, as a result, was originally recorded as a derivative liability. See Note 8 – Derivative Liabilities for additional details. Operating Lease The Company is a party to a lease for 6,800 square feet of space located in Melville, New York (the “Melville Lease”) with respect to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option of the Company for a period of five years) and calls for an annual base rental during the initial term ranging between $132,600 and $149,260. In June 2019, the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term will commence on January 1, 2020 with annual base rent ranging between $153,748 and $173,060. The Company’s rent expense amounted to approximately $20,000 and $74,000 for the three and nine months ended September 30, 2019, respectively. The Company’s rent expense amounted to approximately $31,000 and $92,000 for the three and nine months ended September 30, 2018, respectively. Rent expense is reflected in general and administrative expenses and research and development expenses in the unaudited condensed consolidated statements of operations. Litigations, Claims and Assessments In the normal course of business, the Company may be involved in legal proceedings, claims or assessments arising from the ordinary course of business, and as of September 30, 2019, none are expected to materially impact the Company’s financial position. The Company records legal costs associated with loss contingencies as incurred and accrues for all probable and estimable settlements. Bonus Accruals As of December 31, 2018, the Company had remaining accruals of approximately $91,000 for bonus milestones that were achieved in prior years and remained unpaid. As of September 30, 2019, the remaining accruals for bonus milestones achieved in prior years had been paid in full. In April 2019, the Company’s Compensation Committee and Board of Directors approved performance goals associated with cash bonuses payable to certain officers for the year ending December 31, 2019 and, as a result, the Company accrued $39,114 for 2019 cash bonuses as of September 30, 2019 which were probable to be achieved. Arena Investors In July 2019, the Company entered into a securities purchase agreement (the “Arena Purchase Agreement”) with Arena Investors LP (“Arena”) pursuant to which Arena had agreed to acquire 5,500,000 shares of Series A preferred stock, par value $0.01 per share, of the Company, a warrant for the purchase of 6,000,000 shares of common stock, par value $0.001 per share, of the Company and a convertible promissory note of the Company in the principal amount of $500,000, in consideration of a payment by Arena to the Company of an aggregate of $5,400,000. The closing of the Arena Purchase Agreement was subject to, among other things, approval by the shareholders of the Company of the Arena Purchase Agreement (which was obtained in August 2019) and the transactions contemplated thereby, the concurrent execution of an underwriting agreement with regard to the Public Offering and approval by the Nasdaq Stock Market of the Company’s pending listing application with respect to its shares of common stock. The Arena Purchase Agreement provided that it could be terminated by either party if the closing did not occur by October 31, 2019. On November 1, 2019, the Arena Purchase Agreement was terminated.

Stockholders' Deficiency

Stockholders' Deficiency	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Stockholders' Deficiency	Note 7 – Stockholders’ Deficiency Authorized Capital and 2010 Equity Plan In March 2019, the Board of Directors of the Company approved an increase in the number of authorized shares of common stock to 150,000,000, subject to shareholder approval. Additionally, the Board of Directors approved an increase in the number of authorized shares issuable under the Company’s 2010 Equity Participation Plan to 20,000,000, subject to shareholder approval. In May 2019, such shareholder approval was obtained. In March 2019, the Board of Directors determined to submit to the Company’s shareholders for their approval amendments to the Certificate of Incorporation of the Company (with the Board of Directors having the authority to select and file one such amendment) to effect a reverse split of the Company’s common stock at a ratio of not less than 1-for-2 and not more than 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion. Concurrently, the Board of Directors determined to submit to the Company’s shareholders for their approval a proposal to authorize the Board of Directors, in the event the reverse stock split proposal is approved by the shareholders, in its discretion, to reduce the number of authorized shares of common stock in proportion to the percentage decrease in the number of outstanding shares of common stock resulting from the reverse split (or a lesser decrease in authorized shares of common stock as determined by the Board of Directors in its discretion). In May 2019, the Company’s shareholders approved the foregoing proposals. See Note 9 – Subsequent Events regarding the approval by the Board of Directors and shareholders of an increase in the number of authorized shares of common stock to 300,000,000, as well as the grant to the Board of Directors of authority to adopt an amendment to the Certificate of Incorporation of the Company to effect a reverse split of the Company’s common stock at a ratio of not less than 1-for-2 and not more than 1-for-100. Compensatory Common Stock Issuance During the nine months ended September 30, 2019, the Company issued 75,000 shares of immediately vested common stock valued at $30,000 to a consultant for services rendered. Warrant and Option Valuation The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time, equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued. Common Stock and Warrant Offerings During the nine months ended September 30, 2019, the Company issued an aggregate of 2,191,111 shares of common stock of the Company, five-year immediately vested warrants to purchase an aggregate of 1,135,556 shares of common stock of the Company at exercise prices ranging from $0.85 per share to $1.00 per share and one-year immediately vested warrants to purchase an aggregate of 1,055,555 shares of common stock of the Company at an exercise price of $0.70 per share to certain investors for aggregate gross proceeds of $1,156,000. The warrants had an aggregate grant date fair value of $899,689. The warrants were subject to the Company’s sequencing policy and, as a result, were initially recorded as derivative liabilities. See Note 8 – Derivative Liabilities for additional details. Also see Note 9 – Subsequent Events. Stock Warrants Warrant Compensation See Note 6 – Commitments and Contingences for additional details associated with the issuance of a warrant in connection with a consulting agreement extension. The Company recorded stock–based compensation expense of $0 and $56,000 for the three and nine months ended September 30, 2019, respectively, related to stock warrants issued as compensation, which is reflected as consulting expense in the unaudited condensed consolidated statements of operations. For the three and nine months ended September 30, 2018, the Company recorded stock–based compensation expense of $43,105 and $91,297 respectively, related to stock warrants issued as compensation. Warrant Activity Summary In applying the Black-Scholes option pricing model to warrants granted or issued, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.79% - 1.83 % 2.73% - 2.83 % 1.79% - 2.62 % 1.92% - 2.83 % Contractual term (years) 5.00 5.00 1.00 - 5.00 1.98 - 5.00 Expected volatility 133 % 139 % 133% - 150 % 128% - 139 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the warrants granted during the three and nine months ended September 30, 2019 was approximately $0.28 and $0.41 per share, respectively. The weighted average estimated fair value of the warrants granted during the three and nine months ended September 30, 2018 was approximately $1.24 and $1.23 per share, respectively. A summary of the warrant activity during the nine months ended September 30, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2019 3,483,403 $ 3.63 Issued 2,586,111 0.77 Expired (264,623 ) 5.41 Outstanding, September 30, 2019 5,804,891 $ 2.27 2.1 $ - Exercisable, September 30, 2019 5,804,891 $ 2.27 2.1 $ - The following table presents information related to stock warrants at September 30, 2019: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 0.45 - $0.99 2,586,111 2.9 2,586,111 $ 1.00 - $1.99 844,444 0.3 844,444 $ 2.00 - $2.99 75,000 4.1 75,000 $ 3.00 - $3.99 70,000 3.8 70,000 $ 4.00 - $4.99 1,965,457 1.7 1,965,457 $ 5.00 - $5.99 182,667 1.7 182,667 $ 6.00 - $7.99 40,000 0.8 40,000 $ 8.00 - $9.99 2,500 0.2 2,500 $ 10.00 - $15.00 38,712 0.6 38,712 5,804,891 2.1 5,804,891 See Note 9 – Subsequent Events. Stock Options In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.47 % 2.74 % 1.47% - 2.72% 2.44% - 2.74 % Expected term (years) 10.00 5.01 10.00 5.01 - 9.69 Expected volatility 133 % 139 % 133% - 140% 129% - 139 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % The weighted average estimated fair value of the stock options granted during the three and nine months ended September 30, 2019 was approximately $0.25 and $0.36 per share, respectively. The weighted average estimated fair value of the stock options granted during the three and nine months ended September 30, 2018 was approximately $1.42 and $2.92 per share, respectively. In January 2019, the Company issued the Chairman of the Disc Committee of its Scientific Advisory Board (the “Disc Committee Chairman”) a ten-year option to purchase up to 70,000 shares of the Company’s common stock at an exercise price of $1.00 per share. The options vest ratably over three years on the issuance date anniversaries. The grant date value of the option of $44,247 will be recognized over the expected vesting period as consulting expense in the unaudited condensed consolidated statements of operations. In March 2019, the Board of Directors reduced the exercise price of outstanding stock options for the purchase of an aggregate of 4,631,700 shares of common stock of the Company (with exercise prices ranging between $1.00 and $4.70 per share) to $0.75 per share, which was the closing price for the Company’s common stock on the day prior to determination, as reported by the OTCQB market. The exercise price reduction related to options held by, among others, the Company’s officers, directors, advisors and employees. The incremental value of the modified options compared to the original options, both valued as of the respective modification date, of $452,637 is being recognized over the vesting term of the options, which will be reflected as consulting, research and development, and general and administrative expenses in the amounts of $187,861, $56,856 and $207,920, respectively, in the unaudited condensed consolidated statements of operations. In August 2019, the Company issued the Disc Committee Chairman an immediately vested ten-year option to purchase up to 175,000 shares of the Company’s common stock at an exercise price of $0.26 per share. The grant date value of the option of $43,141 was immediately recognized as consulting expense in the unaudited condensed consolidated statements of operations. A summary of the option activity during the nine months ended September 30, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2019 4,703,785 $ 1.04 Granted 245,000 0.40 Forfeited (39,167 ) 1.49 Outstanding, September 30, 2019 4,909,618 $ 1.01 7.4 $ - Exercisable, September 30, 2019 3,532,455 $ 1.11 6.7 $ - The following table presents information related to stock options at September 30, 2019: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.26 - $0.74 175,000 9.9 175,000 $ 0.75 - $0.99 4,623,367 6.7 3,246,204 $ 1.00 - $5.99 38,751 0.6 38,751 $ 6.00 - $19.99 37,500 4.3 37,500 $ 20.00 - $30.00 35,000 2.5 35,000 4,909,618 6.7 3,532,455 The following table presents information related to stock option expense: Weighted Average For the Three Months Ended For the Nine Months Ended Unrecognized at Remaining September 30, September 30, September 30, Period 2019 2018 2019 2018 2019 (Years) Consulting $ 34,021 $ 163,757 $ 505,669 $ 669,574 $ 147,392 1.1 Research and development 106,085 98,148 352,017 242,586 329,604 1.6 General and administrative 93,939 (488,463 ) 548,840 523,089 539,921 1.1 $ 234,045 $ (226,558 ) $ 1,406,526 $ 1,435,249 $ 1,016,917 1.3 Contemplated Public Offering The Company has filed a registration statement with the Securities and Exchange Commission with regard to the contemplated public offering of its equity securities. The registration statement has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This Form 10-Q shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The contemplated public offering of the Company’s securities will be made only by means of a prospectus. No assurances can be given that the contemplated public offering will be completed on reasonable terms or otherwise.

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Liabilities	Note 8 – Derivative Liabilities The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2019 $ 1,094,607 Issuance of derivative liabilities 5,195,089 Extinguishment of derivative liabilities in connection with convertible note repayments and exchanges (2,557,373 ) Change in fair value of derivative liabilities 268,350 Reclassification of derivative liabilities to equity (2,809,565 ) Ending balance as of September 30, 2019 $ 1,191,108 In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the three and nine months ended September 30, 2019 and 2018, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.54% - 2.16 % 1.93% - 2.94 % 1.54% - 2.62 % 1.22% - 2.94 % Expected term (years) 0.08 - 5.00 0.25 - 5.00 0.02 - 5.00 0.25 - 5.00 Expected volatility 91% - 133 % 120% - 208 % 91% - 156 % 100% - 208 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 % During the nine months ended September 30, 2019, the Company recorded new derivative liabilities in the aggregate amounts of $4,135,200 and $1,059,889 related to the ECOs of certain convertible notes payable and warrants subject to sequencing, respectively. See Note 5 – Notes Payable – Convertible Notes for additional details. See Note 6 – Commitments and Contingencies and Note 7 – Stockholders’ Deficiency for warrants issued and deemed to be derivative liabilities. During the nine months ended September 30, 2019, the Company extinguished an aggregate of $2,557,373 of derivative liabilities in connection with repayments and exchanges of certain convertible notes payable into shares of the Company’s common stock. See Note 5 – Notes Payable – Convertible Notes for additional details. During the nine months ended September 30, 2019, the Company reclassified an aggregate of $2,809,565 of derivative liabilities to equity as a result of a change in the sequencing status. On September 30, 2019, the Company recomputed the fair value of ECOs recorded as derivative liabilities to be $1,142,942. The Company recorded a loss on the change in fair value of these derivative liabilities of $145,238 and $584,840 for the three and nine months ended September 30, 2019, respectively. On September 30, 2019, the Company recomputed the fair value of the derivative liabilities related to outstanding warrants to be $48,166. These warrants are either redeemable for cash equal to the Black-Scholes value, as defined, at the election of the warrant holder upon a fundamental transaction pursuant to the warrant terms or were issued subsequent to the commencement of sequencing. The Company recorded a gain on the change in fair value of these derivative liabilities of $80,201 and $316,490 for the three and nine months ended September 30, 2019, respectively.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events Authorized Capital Subsequent to September 30, 2019, the Board of Directors of the Company approved an increase in the number of authorized shares of common stock to 300,000,000, subject to shareholder approval. On November 13, 2019, such shareholder approval was obtained and the Company filed an amendment to its Certificate of Incorporation to increase its authorized common stock to 300,000,000 shares. Subsequent to September 30, 2019, the Board of Directors determined to submit to the Company’s shareholders for their approval, amendments to the Certificate of Incorporation of the Company (with the Board of Directors having the authority to select and file one such amendment) to effect a reverse split of the Company’s common stock at a ratio of not less than 1-for-2 and not more than 1-for-100, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion. On November 13, 2019, such shareholder approval was obtained. Common Stock and Warrant Offering Subsequent to September 30, 2019, the Company issued 3,333,333 shares of common stock of the Company and a five-year immediately vested warrant for the purchase of 3,333,333 shares of common stock of the Company at an exercise price of $0.20 per share to an investor for gross proceeds of $500,000. In consideration of the purchase, the parties agreed to reduce the exercise prices of an aggregate of 2,111,111 outstanding warrants previously issued to the investor with original exercise prices of $0.70 and $0.85 per share to an exercise price of $0.15 per share and extend certain expiration dates of such outstanding warrants from dates between February 2020 and May 2020 to new expiration dates between February 2024 and May 2024. Related Party Notes Subsequent to September 30, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $150,000 to certain related parties. The convertible notes bear interest at a rate of 12% per annum, payable at maturity, with original maturity dates ranging from April 2020 to May 2020. The notes and the respective accrued interest are convertible at the election of the holder at any time at a conversion price equal to 60% of the fair value of the Company’s common stock. Subsequent to September 30, 2019, the Company repaid a related party note in the principal amount of $25,000 and $3,164 of accrued interest. Convertible Notes Subsequent to September 30, 2019, the Company issued convertible promissory notes in the aggregate principal amount of $1,144,500 to certain lenders for aggregate cash proceeds of $1,038,625. The difference of $105,875 was recorded as a debt discount and will be amortized over the terms of the respective notes. The convertible notes bear interest at a rate of 12% per annum, payable at maturity, with original maturity dates ranging from May 2020 to October 2020. The notes are convertible as follows: (i) $921,500 of aggregate convertible notes and the respective accrued interest are convertible into shares of the Company’s common stock at the election of the holder after the 180th day following the issue date at a conversion price equal to the lower of the closing price on the issuance date or generally 58% of the fair value of the Company’s common stock; (ii) $55,000 of convertible notes and the respective accrued interest are convertible into shares of the Company’s common stock at the election of the holder after the 180 th Subsequent to September 30, 2019, the Company and certain lenders agreed to exchange an aggregate principal amount of $236,062 and aggregate accrued interest of $14,510 of certain convertible notes payable for an aggregate of 3,710,440 shares of the Company’s common stock at exchange prices ranging between $0.05 to $0.12 per share. Subsequent to September 30, 2019, the Company repaid an aggregate principal amount of $1,275,000 of convertible notes payable and $109,038 of the respective aggregate accrued interest. Subsequent to September 30, 2019, the Company and a certain lender agreed to extend the maturity date of a certain convertible promissory note with a principal balance of $91,539 from January 2020 to July 2020. In consideration of the extension, the parties agreed to reduce the conversion price floor of the note from $0.10 per share to $0.01 per share. Other Notes Subsequent to September 30, 2019, the Company issued a lender a note payable in the principal amount of $175,000. The note bears interest at a rate of 15% per annum, payable at maturity, with an original maturity date in November 2019.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited condensed consolidated financial statements of the Company include the accounts of Stem Pearls. All significant intercompany transactions have been eliminated in the consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the periods. The Company’s significant estimates and assumptions include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, warrants issued in connection with notes payable, derivative liabilities and the valuation allowance related to the Company’s deferred tax assets. Certain of the Company’s estimates, including the carrying amount of the intangible assets, could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible that these external factors could have an effect on the Company’s estimates and could cause actual results to differ from those estimates.
Deferred Offering Costs	Deferred Offering Costs Deferred offering costs, which primarily consist of direct, incremental professional fees incurred in connection with preparing for a contemplated public offering of the Company’s equity securities (as described in Note 7 – Stockholders’ Deficiency), are capitalized as non-current assets on the balance sheet. Upon a consummation of such contemplated offering (as to which no assurances can be given), the deferred offering costs will be offset against the equity offering proceeds. As of September 30, 2019, the Company incurred deferred offering costs in the amount of $371,725, of which $265,297 and $92,000 are included in accounts payable and accrued expenses, respectively, on the September 30, 2019 condensed consolidated balance sheet, in connection with such contemplated public offering.
Revenue Recognition	Revenue Recognition On January 1, 2019, the Company adopted Accounting Standards Codification (“ASC”) Topic 606, “Revenue from Contracts with Customers” (“ASC 606”). The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under existing U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The five-step process outlined in the ASC 606 is as follows: Step 1 – Identify the Contract with the Customer – A contract exists when (a) the parties to the contract have approved the contract and are committed to perform their respective obligations, (b) the entity can identify each party’s rights regarding the goods or services to be transferred, (c) the entity can identify the payment terms for the goods or services to be transferred, (d) the contract has commercial substance and it is probable that the entity will collect substantially all of the consideration to which it will be entitled in exchange for the goods or services that will be transferred to the customer. Step 2 – Identify Performance Obligations in the Contract – Upon execution of a contract, the Company identifies as performance obligations each promise to transfer to the customer either (a) goods or services that are distinct or (b) a series of distinct goods or services that are substantially the same and have the same pattern of transfer to the customer. To the extent a contract includes multiple promised goods or services, the Company must apply judgement to determine whether the goods or services are capable of being distinct within the context of the contract. If these criteria are not met, the goods or services are accounted for as a combined performance obligation. Step 3 – Determine the Transaction Price – When (or as) a performance obligation is satisfied, the Company shall recognize as revenue the amount of the transaction price that is allocated to the performance obligation. The contract terms are used to determine the transaction price. Generally, all contracts include fixed consideration. If a contract did include variable consideration, the Company would determine the amount of variable consideration that should be included in the transaction price based on expected value method. Variable consideration would be included in the transaction price, if in the Company’s judgement, it is probable that a significant future reversal of cumulative revenue under the contract would not occur. Step 4 – Allocate the Transaction Price – After the transaction price has been determined, the next step is to allocate the transaction price to each performance obligation in the contract. If the contract only has one performance obligation, the entire transaction price will be applied to that obligation. If the contract has multiple performance obligations, the transaction price is allocated to the performance obligations based on the relative standalone selling price (SSP) at contract inception. Step 5 – Satisfaction of the Performance Obligations (and Recognize Revenue) – Revenue is recognized when (or as) goods or services are transferred to a customer. The Company satisfies each of its performance obligations by transferring control of the promised good or service underlying that performance obligation to the customer. Control is the ability to direct the use of, and obtain substantially all of the remaining benefits from, an asset. It includes the ability to prevent other entities from directing the use of, and obtaining the benefits from, an asset. Indicators that control has passed to the customer include: a present obligation to pay; physical possession of the asset; legal title; risks and rewards of ownership; and acceptance of the asset. Performance obligations can be satisfied at a point in time or over time. The Company recognizes all of its revenue pursuant to a license agreement between the Company and a stem cell treatment company (“SCTC”) entered into in January 2012, as amended in November 2015. Pursuant to the license agreement, the SCTC granted to the Company a license to use certain intellectual property related to, among other things, stem cell disc procedures and the Company has granted to the SCTC a non-exclusive sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay the Company royalties on a per disc procedure basis. The Company recognizes sublicensing and royalty revenue on a per disc procedure basis when the third-party sale occurs. All sales have fixed pricing and there are currently no variable components included in the Company’s revenue. The timing of the Company’s revenue recognition may differ from the timing of receiving royalty payments. A receivable is recorded when revenue is recognized prior to receipt of a royalty payment and the Company has an unconditional right to the royalty payment. Alternatively, when a royalty payment precedes the provision of the related services, the Company records deferred revenue until the performance obligations are satisfied. During the three and nine months ended September 30, 2019, the Company recognized $38,000 and $98,000, respectively, of revenue related to the Company’s sublicenses. During the three and nine months ended September 30, 2018, the Company recognized $26,000 and $82,000, respectively, of revenue related to the Company’s sublicenses. The Company adopted ASC 606 for all applicable contracts using the modified retrospective method, which would have required a cumulative-effect adjustment, if any, as of the date of adoption. The adoption of ASC 606 did not have a material impact on the Company’s unaudited condensed consolidated financial statements as of the date of adoption. As a result, a cumulative-effect adjustment was not required.
Net Loss Per Common Share	Net Loss Per Common Share Basic loss per common share is computed by dividing net loss by the weighted average number of vested common shares outstanding during the period. Diluted earnings per share reflects the potential dilution that could occur if securities or other instruments to issue common stock were exercised or converted into common stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2019 2018 Options 4,909,618 3,588,451 Warrants 5,804,891 3,413,403 Convertible notes - common stock [1] 35,373,991 2,986,487 Convertible notes - warrants 2,776,450 - Total potentially dilutive shares 48,864,950 9,988,341 [1] As of September 30, 2019 and 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, on September 30, 2019 and September 30, 2018 there were 110,370,828 and 24,710,731 shares of common stock reserved for future note conversions, respectively. See Note 9 – Subsequent Events regarding the Board of Directors approval to increase the number of authorized shares of common stock, subject to shareholder approval.
Stock-Based Compensation	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. The fair value of the award is measured on the grant date and is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. The Company estimates the fair value of the awards granted based on the market value of its freely tradable common stock as reported on the OTCQB market. Upon the exercise of an option or warrant, the Company issues new shares of common stock out of its authorized shares.
Derivative Financial Instruments	Derivative Financial Instruments The Company evaluates its convertible instruments to determine if those contracts or embedded components of those contracts qualify as derivative financial instruments to be separately accounted for in accordance with Topic 815 of the Financial Accounting Standards Board (“FASB”) ASC. The accounting treatment of derivative financial instruments requires that the Company record embedded conversion options (“ECOs”) and any related freestanding instruments at their fair values as of the inception date of the agreement and at fair value as of each subsequent balance sheet date. Any change in fair value is recorded as non-operating, non-cash income or expense for each reporting period at each balance sheet date. Conversion options are recorded as a discount to the host instrument and are amortized as amortization of debt discount on the unaudited condensed consolidated financial statements over the life of the underlying instrument. The Company reassesses the classification of its derivative instruments at each balance sheet date. If the classification changes as a result of events during the period, the contract is reclassified as of the date of the event that caused the reclassification. The Multinomial Lattice Model and Black-Scholes Model were used to estimate the fair value of the ECOs of convertible notes payable, the warrants, and stock options that are classified as derivative liabilities on the unaudited condensed consolidated balance sheets. The models include subjective input assumptions that can materially affect the fair value estimates. The expected volatility is estimated based on the actual volatility during the most recent historical period of time equal to the weighted average life of the instruments.
Sequencing Policy	Sequencing Policy Under ASC 815-40-35 (“ASC 815”), the Company has adopted a sequencing policy, whereby, in the event that reclassification of contracts from equity to assets or liabilities is necessary pursuant to ASC 815 due to the Company’s inability to demonstrate it has sufficient authorized shares as a result of certain securities with a potentially indeterminable number of shares, shares will be allocated on the basis of the earliest issuance date of potentially dilutive instruments, with the earliest grants receiving the first allocation of shares. Pursuant to ASC 815, issuances of securities to the Company’s employees and directors, or to compensate grantees in a share-based payment arrangement, are not subject to the sequencing policy.
Reclassification	Reclassification Certain amounts in prior periods have been reclassified to conform to the current period presentation. These reclassifications had no effect on previously reported net loss.
Subsequent Events	Subsequent Events The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued. Based upon the evaluation, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the unaudited condensed consolidated financial statements, except as disclosed.
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In February 2016, the FASB issued Accounting Standards Update (“ASU”) 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). ASU 2016-02 requires that a lessee recognize the assets and liabilities that arise from operating leases. A lessee should recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of 12 months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and lease liabilities. In transition, lessees and lessors are required to recognize and measure leases at the beginning of the earliest period presented using a modified retrospective approach. This amendment will be effective for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The FASB issued ASU No. 2018-10 “Codification Improvements to Topic 842, Leases” (“ASU 2018-10”), ASU No. 2018-11 “Leases (Topic 842) Targeted Improvements” (“ASU 2018-11”) in July 2018, and ASU No. 2018-20 “Leases (Topic 842) - Narrow Scope Improvements for Lessors” (“ASU 2018-20”) in December 2018. ASU 2018-10 and ASU 2018-20 provide certain amendments that affect narrow aspects of the guidance issued in ASU 2016-02. ASU 2018-11 allows all entities adopting ASU 2016-02 to choose an additional (and optional) transition method of adoption, under which an entity initially applies the new leases standard at the adoption date and recognizes a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company is currently evaluating these ASUs and their impact on its unaudited condensed consolidated financial statements. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230) Classification of Certain Cash Receipts and Cash Payments”. The new standard will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. The new standard is effective for fiscal years beginning after December 15, 2018. The Company has adopted this standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In June 2018, the FASB issued ASU No. 2018-07, “Compensation — Stock Compensation (Topic 718)” (“ASU 2018-07”). ASU 2018-07 is intended to reduce cost and complexity and to improve financial reporting for nonemployee share-based payments. Currently, the accounting requirements for nonemployee and employee share-based payment transactions are significantly different. ASU 2018-07 expands the scope of Topic 718, Compensation — Stock Compensation (which currently only includes share-based payments to employees) to include share-based payments issued to nonemployees for goods or services. Consequently, the accounting for share-based payments to nonemployees and employees will be substantially aligned. This ASU supersedes Subtopic 505-50, Equity — Equity-Based Payments to Nonemployees. The amendments in this ASU are effective for fiscal years beginning after December 15, 2019 and including interim periods within that fiscal year. Early adoption is permitted, but no earlier than a company’s adoption date of Topic 606, Revenue from Contracts with Customers. The Company early adopted this accounting standard as of January 1, 2019. The adoption of this standard did not have a material impact on the Company’s unaudited condensed consolidated financial statements and financial statement disclosures. In March 2019, the FASB issued ASU 2019-01, “Leases (Topic 842): Codification Improvements” (“Topic 842”) (“ASU 2019-01”). These amendments align the guidance for fair value of the underlying asset by lessors that are not manufacturers or dealers in Topic 842 with that of existing guidance. As a result, the fair value of the underlying asset at lease commencement is its cost, reflecting any volume or trade discounts that may apply. However, if there has been a significant lapse of time between when the underlying asset is acquired and when the lease commences, the definition of fair value (in Topic 820, Fair Value Measurement) should be applied. (Issue 1). The ASU also requires lessors within the scope of Topic 942, Financial Services—Depository and Lending, to present all “principal payments received under leases” within investing activities. (Issue 2). Finally, the ASU exempts both lessees and lessors from having to provide certain interim disclosures in the fiscal year in which a company adopts the new leases standard. (Issue 3). The transition and effective date provisions apply to Issue 1 and Issue 2. They do not apply to Issue 3 because the amendments for that Issue are to the original transition requirements in Topic 842. This amendment will be effective for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. Early adoption is permitted. The Company is currently evaluating ASU 2019-01 and its impact on its unaudited condensed consolidated financial statements and financial statement disclosures. In July 2019, the FASB issued ASU 2019-07, “Codification Updates to SEC Sections — Amendments to SEC Paragraphs Pursuant to SEC Final Rule Releases No. 33-10532, Disclosure Update and Simplification, and Nos. 33-10231 and 33-10442, Investment Company Reporting Modernization and Miscellaneous Updates (SEC Update)” (“ASU 2019-07”). ASU 2019-07 aligns the guidance in various SEC sections of the Codification with the requirements of certain SEC final rules. ASU 2019-07 is effective immediately. The adoption of ASU 2019-07 did not have a material impact on the Company’s unaudited condensed consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Schedule of Weighted Average Dilutive Common Shares	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: September 30, 2019 2018 Options 4,909,618 3,588,451 Warrants 5,804,891 3,413,403 Convertible notes - common stock [1] 35,373,991 2,986,487 Convertible notes - warrants 2,776,450 - Total potentially dilutive shares 48,864,950 9,988,341 [1] As of September 30, 2019 and 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, on September 30, 2019 and September 30, 2018 there were 110,370,828 and 24,710,731 shares of common stock reserved for future note conversions, respectively. See Note 9 – Subsequent Events regarding the Board of Directors approval to increase the number of authorized shares of common stock, subject to shareholder approval.

Accrued Expenses and Other Cu_2

Accrued Expenses and Other Current Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Accrued Liabilities and Other Liabilities [Abstract]
Schedule of Accrued Expenses and Other Current Liabilities	Accrued expenses and other current liabilities are comprised of the following: September 30, 2019 December 31, 2018 Accrued payroll and other accrued expenses $ 43,779 $ 91,560 Accrued research and development expenses 746,175 646,175 Accrued general and administrative expenses 1,320,104 1,084,831 Accrued director compensation 507,500 482,500 Deferred rent 7,865 33,610 Total accrued expenses 2,625,423 2,338,676 Less: accrued expenses, current portion 2,625,423 2,302,176 Accrued expenses, non-current portion $ - $ 36,500

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Schedule of Notes Payable Activity	A summary of the notes payable activity during the nine months ended September 30, 2019 is presented below: Related Party Convertible Other Debt Notes Notes Notes Discount Total Outstanding, January 1, 2019 $ 720,000 $ 4,309,415 $ 132,501 $ (1,012,363 ) $ 4,149,553 Issuances 485,000 8,543,089 [1] - - 9,028,089 Exchanges for equity - (2,032,323 ) - 455,969 (1,576,354 ) Repayments (45,000 ) (3,484,105 ) (7,500 ) 428,939 (3,107,666 ) Extinguishment of notes payable - - (148,014 )[1] 6,196 (141,818 ) Recognition of debt discount - - - (4,288,794 ) (4,288,794 ) Accretion of interest expense - - - 375,344 375,344 Accrued interest reclassified to notes payable principal - - 23,013 - 23,013 Amortization of debt discount - - - 3,221,904 3,221,904 Outstanding, September 30, 2019 [2] $ 1,160,000 $ 7,336,076 [3] $ - $ (812,805 ) $ 7,683,271 [1] During the nine months ended September 30, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 – Notes Payable – Convertible Notes - Conversions, Exchanges and Other for additional details. [2] As of September 30, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amounts of $450,000, $508,000 and $0, respectively, were considered past due (which excludes aggregate principal amounts of $25,000 and $150,000 of related party and convertible notes, respectively, which were extended to October 2019, effective as of September 30, 2019). See Note 9 – Subsequent Events for details regarding the repayment of certain past due notes payable. [3] As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $4,381,076 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $2,955,000, which are not currently convertible, will become convertible into shares of the Company’s common stock at the election of the respective holder subsequent to September 30, 2019. As of September 30, 2019, outstanding related party notes and convertible notes in the aggregate principal amounts of $1,150,000 and $990,000, respectively, provided for a mandatory conversion into common stock of the Company and warrants to purchase common stock of the Company in the same ratio upon the completion of an underwritten public offering by the Company. See Note 9 – Subsequent Events.

Stockholders' Deficiency (Table

Stockholders' Deficiency (Tables)	9 Months Ended
	Sep. 30, 2019
Stockholders' Equity Note [Abstract]
Schedule of Warrants Granted Assumptions	In applying the Black-Scholes option pricing model to warrants granted or issued, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.79% - 1.83 % 2.73% - 2.83 % 1.79% - 2.62 % 1.92% - 2.83 % Contractual term (years) 5.00 5.00 1.00 - 5.00 1.98 - 5.00 Expected volatility 133 % 139 % 133% - 150 % 128% - 139 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Warrant Activity	A summary of the warrant activity during the nine months ended September 30, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Warrants Price In Years Value Outstanding, January 1, 2019 3,483,403 $ 3.63 Issued 2,586,111 0.77 Expired (264,623 ) 5.41 Outstanding, September 30, 2019 5,804,891 $ 2.27 2.1 $ - Exercisable, September 30, 2019 5,804,891 $ 2.27 2.1 $ -
Schedule of Stock Warrants	The following table presents information related to stock warrants at September 30, 2019: Warrants Outstanding Warrants Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Warrants In Years Warrants $ 0.45 - $0.99 2,586,111 2.9 2,586,111 $ 1.00 - $1.99 844,444 0.3 844,444 $ 2.00 - $2.99 75,000 4.1 75,000 $ 3.00 - $3.99 70,000 3.8 70,000 $ 4.00 - $4.99 1,965,457 1.7 1,965,457 $ 5.00 - $5.99 182,667 1.7 182,667 $ 6.00 - $7.99 40,000 0.8 40,000 $ 8.00 - $9.99 2,500 0.2 2,500 $ 10.00 - $15.00 38,712 0.6 38,712 5,804,891 2.1 5,804,891
Schedule of Stock Option Granted Assumptions	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.47 % 2.74 % 1.47% - 2.72% 2.44% - 2.74 % Expected term (years) 10.00 5.01 10.00 5.01 - 9.69 Expected volatility 133 % 139 % 133% - 140% 129% - 139 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %
Schedule of Stock Option Activity	A summary of the option activity during the nine months ended September 30, 2019 is presented below: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Life Intrinsic Options Price In Years Value Outstanding, January 1, 2019 4,703,785 $ 1.04 Granted 245,000 0.40 Forfeited (39,167 ) 1.49 Outstanding, September 30, 2019 4,909,618 $ 1.01 7.4 $ - Exercisable, September 30, 2019 3,532,455 $ 1.11 6.7 $ -
Schedule of Stock Option by Exercise Price	The following table presents information related to stock options at September 30, 2019: Options Outstanding Options Exercisable Weighted Outstanding Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 0.26 - $0.74 175,000 9.9 175,000 $ 0.75 - $0.99 4,623,367 6.7 3,246,204 $ 1.00 - $5.99 38,751 0.6 38,751 $ 6.00 - $19.99 37,500 4.3 37,500 $ 20.00 - $30.00 35,000 2.5 35,000 4,909,618 6.7 3,532,455
Schedule of Stock Option Expense	The following table presents information related to stock option expense: Weighted Average For the Three Months Ended For the Nine Months Ended Unrecognized at Remaining September 30, September 30, September 30, Period 2019 2018 2019 2018 2019 (Years) Consulting $ 34,021 $ 163,757 $ 505,669 $ 669,574 $ 147,392 1.1 Research and development 106,085 98,148 352,017 242,586 329,604 1.6 General and administrative 93,939 (488,463 ) 548,840 523,089 539,921 1.1 $ 234,045 $ (226,558 ) $ 1,406,526 $ 1,435,249 $ 1,016,917 1.3

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Summary of Changes in Fair Value of Level 3 Derivative Liabilities	The following table sets forth a summary of the changes in the fair value of Level 3 derivative liabilities that are measured at fair value on a recurring basis: Beginning balance as of January 1, 2019 $ 1,094,607 Issuance of derivative liabilities 5,195,089 Extinguishment of derivative liabilities in connection with convertible note repayments and exchanges (2,557,373 ) Change in fair value of derivative liabilities 268,350 Reclassification of derivative liabilities to equity (2,809,565 ) Ending balance as of September 30, 2019 $ 1,191,108
Summary of Derivative Liabilities Fair Value Assumption	In applying the Multinomial Lattice and Black-Scholes option pricing models to derivatives issued and outstanding during the three and nine months ended September 30, 2019 and 2018, the Company used the following assumptions: For the Three Months Ended For the Nine Months Ended September 30, September 30, 2019 2018 2019 2018 Risk free interest rate 1.54% - 2.16 % 1.93% - 2.94 % 1.54% - 2.62 % 1.22% - 2.94 % Expected term (years) 0.08 - 5.00 0.25 - 5.00 0.02 - 5.00 0.25 - 5.00 Expected volatility 91% - 133 % 120% - 208 % 91% - 156 % 100% - 208 % Expected dividends 0.00 % 0.00 % 0.00 % 0.00 %

Going Concern and Management'_2

Going Concern and Management's Plans (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		4 Months Ended	9 Months Ended
	Nov. 14, 2019	Sep. 30, 2019	Sep. 30, 2018	Aug. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Jun. 30, 2019	Dec. 31, 2018	Jun. 30, 2018	Dec. 31, 2017
Working capital deficiency		$ 13,514,377			$ 13,514,377
Stockholder's deficiency		12,428,533	$ 8,938,147		12,428,533	$ 8,938,147	$ 8,942,471	$ 8,641,038	$ 9,868,013	$ 6,836,568
Net loss		5,056,973	$ 2,925,261		13,097,335	$ 8,947,344
Repayments of debt					(3,107,666)
Note payable past due		$ 593,400			$ 593,400
Principal amount of notes agreed to exchange for shares in connection with closing of public offering				$ 1,565,000
Subsequent Event [Member]
Aggregate equity financings	$ 500,000
Repayments of debt	1,412,202
Subsequent Event [Member] | July 2020 [Member]
Repayments of debt	$ 91,539

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Accounting Policies [Abstract]
Deferred offering cost	$ 371,725		$ 371,725
Accounts payable	265,297		265,297
Accrued expenses	92,000		92,000
Royalty revenue	$ 38,000	$ 26,000	$ 98,000	$ 82,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) - shares		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018
Total potentially dilutive shares		48,864,950	9,988,341
Options [Member]
Total potentially dilutive shares		4,909,618	3,588,451
Warrants [Member]
Total potentially dilutive shares		5,804,891	3,413,403
Convertible Notes - Common Stock [Member]
Total potentially dilutive shares	[1]	35,373,991	2,986,487
Convertible Notes - Warrants [Member]
Total potentially dilutive shares		2,776,450
[1]	As of September 30, 2019 and 2018, many of the convertible notes had variable conversion prices and the shares were estimated based on market conditions. Pursuant to the note agreements, on September 30, 2019 and September 30, 2018 there were 110,370,828 and 24,710,731 shares of common stock reserved for future note conversions, respectively. See Note 9 - Subsequent Events regarding the Board of Directors approval to increase the number of authorized shares of common stock, subject to shareholder approval.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Schedule of Weighted Average Dilutive Common Shares (Details) (Parenthetical) - shares	Sep. 30, 2019	Sep. 30, 2018
Accounting Policies [Abstract]
Common stock, reserved for future issuance	110,370,828	24,710,731

Accrued Expenses and Other Cu_3

Accrued Expenses and Other Current Liabilities (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Gain (loss) on settlement of notes payable, net	$ 1,290,623	$ 320,383	$ 2,291,218	$ 384,171
Settlement Agreement [Member] | Consultant [Member]
Accrued consulting fees	$ 46,500		$ 46,500
Stock issued in exchange of consulting fees			10,000
Payment of consulting fees			$ 10,000
Common stock aggregate grant date value			7,200
Gain (loss) on settlement of notes payable, net			$ 29,300

Accrued Expenses and Other Cu_4

Accrued Expenses and Other Current Liabilities - Schedule of Accrued Expenses and Other Current Liabilities (Details) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Accrued Liabilities and Other Liabilities [Abstract]
Accrued payroll and other accrued expenses	$ 43,779	$ 91,560
Accrued research and development expenses	746,175	646,175
Accrued general and administrative expenses	1,320,104	1,084,831
Accrued director compensation	507,500	482,500
Deferred rent	7,865	33,610
Total accrued expenses	2,625,423	2,338,676
Less: accrued expenses, current portion	2,625,423	2,302,176
Accrued expenses, non-current portion		$ 36,500

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended			9 Months Ended
	Oct. 31, 2019	Sep. 30, 2019		Sep. 30, 2018	Sep. 30, 2019		Sep. 30, 2018	Dec. 31, 2018
Debt Instrument [Line Items]
Payment of notes payable					$ 3,536,605		$ 351,571
Loss on extinguishment of notes payable		$ (1,290,623)		$ (320,383)	(2,291,218)		(384,171)
Extinguished debt					141,818
Notes payable		$ 7,683,271	[1]		$ 7,683,271	[1]		$ 4,149,553
Warrants to purchase common stock		5,804,891			5,804,891
Warrant term		2 years 1 month 6 days			2 years 1 month 6 days
Debt conversion, converted instrument, amount				$ 57,732			$ 110,636
Original issuance debt discount		$ 733,886			$ 733,886			$ 936,866
Common stock, shares issued		23,717,754			23,717,754			11,728,394
Repayments of debt					$ (3,107,666)
Related Party Notes [Member]
Debt Instrument [Line Items]
Payment of notes payable					45,000
Convertible notes payable aggregate principal amount		$ 485,000			$ 485,000
Debt instrument, convertible, conversion price		$ 0.60			$ 0.60
Warrant term		5 years			5 years
Warrant exercise price		$ 0.80			$ 0.80
Related Party Notes [Member] | September 2019 to October 2019 [Member]
Debt Instrument [Line Items]
Notes payable		$ 25,000			$ 25,000
Related Party Notes [Member] | Scientific Advisory Board Member [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 485,000			$ 485,000
Interest rate		12.00%			12.00%
Debt maturity period					Maturity dates between July 2019 and December 2019.
Related Party Notes [Member] | Holders [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 505,000			$ 505,000
Debt maturity period					Extended from dates from December 2018 and August 2019 to dates between July 2019 and December 2019
Convertible notes payable aggregate principal amount		$ 475,000			$ 475,000
Offering price percentage					75.00%
Shares issued price per share		$ 0.60			$ 0.60
Warrant description					The exchange price of the warrants to be issued to such holders will be the lesser of (i) 125% of the Exchange Price or (ii) $0.80 per share (subject to adjustment for reverse stock splits and the like).
Embedded conversion option percentage					10.00%
Loss on extinguishment of notes payable					$ 145,066
Extinguished debt					510,887
Accrued interest		$ 35,887			35,887
Fair value of embedded conversion option					145,066
Related Party Notes [Member] | Director [Member]
Debt Instrument [Line Items]
Debt principal amount		175,000			175,000
Related Party Notes [Member] | Trust [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 500,000			$ 500,000
Related Party Notes [Member] | Director and Trust [Member]
Debt Instrument [Line Items]
Offering price percentage					75.00%
Warrant description					The exercise price of the warrants to be issued to the director and the Trust will be 125% of the Director/Trust Exchange Price and the term of the warrants will be the same term as the Public Warrants. Concurrently with the exchange, the exercise prices of outstanding warrants held by the director and the Trust for the purchase of an aggregate of 1,377,842 shares of common stock of the Company will be reduced from between $1.50 and $4.00 per share to $0.75 per share and the expiration dates of such warrants will be extended from between December 2019 and March 2022 to December 2023.
Warrants to purchase common stock		1,377,842			1,377,842
Convertible Notes [Member]
Debt Instrument [Line Items]
Debt maturity period					Original maturity dates ranging between July 2019 through September 2020
Convertible notes payable aggregate principal amount		$ 8,395,075			$ 8,395,075
Loss on extinguishment of notes payable					$ 1,242,669
Warrants to purchase common stock		295,000			295,000
Warrant term		5 years			5 years
Proceeds from convertible debt					$ 7,847,727
Original issuance debt discount		$ 547,348			$ 547,348
Number of shares of common stock issued					68,873
Debt discount		54,168			$ 54,168
Fair value of warrant		104,198			104,198
Convertible debt fair value		148,014			148,014
Repayments of debt					209,486
Aggregate principal on prepayment premiums		$ 813,730			813,730
Extinguishments of debt discounts					$ 428,939
Convertible Notes [Member] | Minimum [Member]
Debt Instrument [Line Items]
Warrant exercise price		$ 0.45			$ 0.45
Debt instrument interest rate		8.00%			8.00%
Convertible Notes [Member] | Maximum [Member]
Debt Instrument [Line Items]
Warrant exercise price		$ 1			$ 1
Debt instrument interest rate		15.00%			15.00%
Embedded Conversion Options and Note Provisions [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 4,381,076			$ 4,381,076
Offering price percentage					75.00%
Embedded Conversion Options and Note Provisions [Member] | Convertible Notes [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		2,955,000			$ 2,955,000
Debt instrument convertible conversion ratio					0.58
Embedded Conversion Options and Note Provisions [Member] | Convertible Notes One [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 4,325,075			$ 4,325,075
Percentage on prepayment premium		35.00%			35.00%
Embedded Conversion Options and Note Provisions [Member] | Convertible Notes Two [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 4,252,688			$ 4,252,688
Debt instrument convertible conversion ratio					0.58
Embedded Conversion Options and Note Provisions [Member] | ECO [Member]
Debt Instrument [Line Items]
Loss on extinguishment of notes payable					$ 414,108
Fair value of embedded conversion option					3,990,135
Original issuance debt discount		3,576,028			3,576,028
Embedded Conversion Options and Note Provisions [Member] | Underwritten Public Offering [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		990,000			990,000
Embedded Conversion Options and Note Provisions 1 [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 2,355,076			$ 2,355,076
Debt instrument convertible conversion ratio					0.58
Embedded Conversion Options and Note Provisions 1 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 0.25			$ 0.25
Embedded Conversion Options and Note Provisions 1 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 2			$ 2
Embedded Conversion Options and Note Provisions 2 [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 1,046,000			$ 1,046,000
Embedded Conversion Options and Note Provisions 2 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio					0.58
Embedded Conversion Options and Note Provisions 2 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument convertible conversion ratio					0.65
Embedded Conversion Options and Note Provisions 3 [Member]
Debt Instrument [Line Items]
Convertible notes payable aggregate principal amount		$ 980,000			$ 980,000
Warrant term		5 years			5 years
Embedded Conversion Options and Note Provisions 3 [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 0.50			$ 0.50
Warrant exercise price		0.75			0.75
Embedded Conversion Options and Note Provisions 3 [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		0.60			0.60
Warrant exercise price		$ 0.80			$ 0.80
Conversions, Exchanges and Other [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 2,032,323			$ 2,032,323
Loss on extinguishment of notes payable					483,179
Extinguished debt					141,818
Accrued interest		122,111			122,111
Fair value of embedded conversion option					4,255,838
Debt conversion, converted instrument, amount					4,739,017
Original issuance debt discount		455,969			455,969
Derivative liability		$ 2,557,373			$ 2,557,373
Common stock, shares issued		9,634,376			9,634,376
Repayments of debt					$ 3,484,105
Accrued interest reclassified to principal		$ 23,013			23,013
Conversions, Exchanges and Other [Member] | Promissory Note [Member]
Debt Instrument [Line Items]
Debt principal amount		148,014			148,014
Conversions, Exchanges and Other [Member] | New Convertible Note [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 148,014			$ 148,014
Debt maturity period					Maturity date in March 2020
Embedded conversion option percentage					10.00%
Loss on extinguishment of notes payable					$ 90,994
Fair value of embedded conversion option					$ 84,798
Debt instrument interest rate		12.00%			12.00%
Derivative liability		$ 84,798			$ 84,798
Debt conversion fair value percentage					10.00%
Conversions, Exchanges and Other [Member] | Minimum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 0.11			$ 0.11
Conversions, Exchanges and Other [Member] | Maximum [Member]
Debt Instrument [Line Items]
Debt instrument, convertible, conversion price		$ 0.43			$ 0.43
Conversions, Exchanges and Other [Member] | Lenders [Member]
Debt Instrument [Line Items]
Debt principal amount	$ 150,000	$ 678,102			$ 678,102
Debt maturity period	Maturity dates in September 2019 to new maturity dates in October 2019				Maturity dates ranging from June 2019 to July 2019 to new maturity dates ranging from July 2019 to July 2020.
Convertible notes payable aggregate principal amount		650,000			$ 650,000
Offering price percentage					75.00%
Embedded conversion option percentage					10.00%
Loss on extinguishment of notes payable					$ 329,310
Extinguished debt					702,387
Accrued interest		$ 52,387			52,387
Fair value of embedded conversion option					$ 329,310
Warrant term		5 years			5 years
Other Notes [Member] | Lenders [Member]
Debt Instrument [Line Items]
Debt principal amount		$ 125,000			$ 125,000
Debt maturity period					Maturity date in January 2019 to a new maturity date in December 2019
Convertible notes payable aggregate principal amount		148,014			$ 148,014
Original issuance debt discount		$ 7,052			$ 7,052
Common stock, shares issued		10,000			10,000
Repayments of debt					$ 7,500
[1]	As of September 30, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amounts of $450,000, $508,000 and $0, respectively, were considered past due (which excludes aggregate principal amounts of $25,000 and $150,000 of related party and convertible notes, respectively, which were extended to October 2019, effective as of September 30, 2019). See Note 9 - Subsequent Events for details regarding the repayment of certain past due notes payable.

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable Activity (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Outstanding beginning				$ 4,149,553
Issuances				9,028,089
Exchanges for equity				(1,576,354)
Repayments				3,107,666
Extinguishment of notes payable				(141,818)
Recognition of debt discount				(4,288,794)
Accretion of interest expense				375,344	$ 427,908
Accrued interest reclassified to notes payable principal				23,013
Amortization of debt discount		$ 1,487,501	$ 540,488	3,221,904	$ 1,884,116
Outstanding ending	[1]	7,683,271		7,683,271
Related Party Notes [Member]
Outstanding beginning				720,000
Issuances				485,000
Exchanges for equity
Repayments				(45,000)
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal
Amortization of debt discount
Outstanding ending	[1]	1,160,000		1,160,000
Convertible Notes [Member]
Outstanding beginning				4,309,415
Issuances	[2]			8,543,089
Exchanges for equity				(2,032,323)
Repayments				(3,484,105)
Extinguishment of notes payable
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal
Amortization of debt discount
Outstanding ending	[1],[3]	7,336,076		7,336,076
Other Notes [Member]
Outstanding beginning				132,501
Issuances
Exchanges for equity
Repayments				(7,500)
Extinguishment of notes payable	[2]			(148,014)
Recognition of debt discount
Accretion of interest expense
Accrued interest reclassified to notes payable principal				23,013
Amortization of debt discount
Outstanding ending	[1]
Debt Discount [Member]
Outstanding beginning				(1,012,363)
Issuances
Exchanges for equity				455,969
Repayments				428,939
Extinguishment of notes payable				6,196
Recognition of debt discount				(4,288,794)
Accretion of interest expense				375,344
Accrued interest reclassified to notes payable principal
Amortization of debt discount				3,221,904
Outstanding ending	[1]	$ (812,805)		$ (812,805)
[1]	As of September 30, 2019, outstanding related party notes, convertible notes and other notes in the aggregate principal amounts of $450,000, $508,000 and $0, respectively, were considered past due (which excludes aggregate principal amounts of $25,000 and $150,000 of related party and convertible notes, respectively, which were extended to October 2019, effective as of September 30, 2019). See Note 9 - Subsequent Events for details regarding the repayment of certain past due notes payable.
[2]	During the nine months ended September 30, 2019, a convertible note in the principal amount of $148,014 was issued concurrently with the extinguishment of a certain note payable in the same aggregate principal amount. See below within Note 5 - Notes Payable - Convertible Notes - Conversions, Exchanges and Other for additional details.
[3]	As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $4,381,076 were convertible into shares of common stock at the election of the holder any time until the balance has been paid in full. As of September 30, 2019, a portion of convertible notes with an aggregate principal balance of $2,955,000, which are not currently convertible, will become convertible into shares of the Company's common stock at the election of the respective holder subsequent to September 30, 2019. As of September 30, 2019, outstanding related party notes and convertible notes in the aggregate principal amounts of $1,150,000 and $990,000, respectively, provided for a mandatory conversion into common stock of the Company and warrants to purchase common stock of the Company in the same ratio upon the completion of an underwritten public offering by the Company. See Note 9 - Subsequent Events.

Notes Payable - Schedule of N_2

Notes Payable - Schedule of Notes Payable Activity (Details) (Parenthetical) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt conversion, converted instrument, amount	$ 57,732		$ 110,636
Convertible Notes [Member]
Debt instrument, face amount		$ 148,014
Debt conversion, converted instrument, amount		4,381,076
Convertible notes with a principal balance		2,955,000
Related Party Notes [Member]
Debt instrument, face amount		450,000
Related Party Notes [Member] | Underwritten Public Offering [Member]
Debt conversion, converted instrument, amount		1,150,000
Related Party Notes [Member] | Extended to October 2019 [Member]
Debt instrument, face amount		25,000
Convertible Notes [Member]
Debt instrument, face amount		508,000
Convertible Notes [Member] | Underwritten Public Offering [Member]
Debt conversion, converted instrument, amount		990,000
Convertible Notes [Member] | Extended to October 2019 [Member]
Debt instrument, face amount		150,000
Other Notes [Member]
Debt instrument, face amount		$ 0

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative)	1 Months Ended			3 Months Ended		9 Months Ended
	Jul. 31, 2019USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	Jan. 31, 2019USD ($)$ / sharesshares	Sep. 30, 2019USD ($)ft²$ / sharesshares	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)ft²$ / sharesshares	Sep. 30, 2018USD ($)	Dec. 31, 2018USD ($)$ / shares
Warrant term				2 years 1 month 6 days		2 years 1 month 6 days
Warrants to purchase common stock | shares				5,804,891		5,804,891
Rent expense				$ 20,000	$ 31,000	$ 74,000	$ 92,000
Accrued bonuses								$ 91,000
Preferred stock, par value | $ / shares				$ 0.01		$ 0.01		$ 0.01
Common stock, par value | $ / shares				$ 0.001		$ 0.001		$ 0.001
2019 Bonus [Member]
Accrued bonuses				$ 39,114		$ 39,114
Melville Lease [Member]
Area of land | ft²				6,800		6,800
Lease expire date						Mar. 31, 2020
Lease description		The Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term will commence on January 1, 2020				The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option of the Company for a period of five years)
Melville Lease [Member] | Minimum [Member]
Rent expense		$ 153,748				$ 132,600
Melville Lease [Member] | Maximum [Member]
Rent expense		$ 173,060				$ 149,260
Consulting Agreements [Member] | Business Advisory Services [Member]
Consulting agreements expires date			Dec. 31, 2019
Consulting agreements, description			An agreement for business advisory services that had expired on December 31, 2018 was further extended and now provides for an expiration date of December 31, 2019
Warrant term			5 years
Warrants to purchase common stock | shares			100,000
Exercise price per share | $ / shares			$ 1
Fair value of aggregate of warrant			$ 56,000
Securities Purchase Agreements [Member] | Arena Investors LP [Member]
Warrants to purchase common stock | shares	6,000,000
Common stock, par value | $ / shares	$ 0.001
Aggregate principal amount of convertible notes payable	$ 500,000
Proceeds from convertible promissory note	$ 5,400,000
Securities Purchase Agreements [Member] | Arena Investors LP [Member] | Series A Preferred Stock [Member]
Number of shares issued | shares	5,500,000
Preferred stock, par value | $ / shares	$ 0.01

Stockholders' Deficiency (Detai

Stockholders' Deficiency (Details Narrative) - USD ($)	1 Months Ended				3 Months Ended		9 Months Ended
	Nov. 14, 2019	Aug. 31, 2019	Mar. 31, 2019	Jan. 31, 2019	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Common stock, shares authorized					300,000,000		300,000,000		300,000,000
Number of shares issued for consulting services							$ 7,200
Warrants to purchase common stock					5,804,891		5,804,891
Warrant term					2 years 1 month 6 days		2 years 1 month 6 days
Stock based compensation expenses							$ 1,492,527	$ 1,579,046
Exercise prices of stock options							$ 0.4
Consulting					$ 373,975	$ 417,601	$ 1,507,582	1,268,485
Research and development					409,815	357,436	1,306,544	1,137,381
General and administrative					$ 917,027	$ 284,472	$ 3,279,145	$ 2,932,162
Warrants [Member]
Weighted average estimated fair value of warrants granted per share					$ 0.28	$ 1.24	$ 0.41	$ 1.23
Stock Option [Member]
Weighted average estimated fair value of options granted per share					$ 0.25	$ 1.42	$ 0.36	$ 2.92
Exercise prices of stock options		$ 0.26	$ 0.75	$ 1
Option term				10 years
Stock option vesting term		10 years		3 years
Number of option issued to purchase shares of common stock		175,000	4,631,700	70,000
Grant date value of option		$ 43,141		$ 44,247
Incremental value of modified stock options			$ 452,637
Consulting			187,861
Research and development			56,856
General and administrative			$ 207,920
Common Stock and Warrant Offering [Member]
Warrants to purchase common stock					2,191,111		2,191,111
Aggregate gross proceeds of warrants							$ 1,156,000
Fair value adjustment of warrants							$ 899,689
Common Stock and Warrant Offering [Member] | Five-Year Immediately Vested [Member]
Warrants to purchase common stock					1,135,556		1,135,556
Warrant term					5 years		5 years
Common Stock and Warrant Offering [Member] | One-Year Immediately Vested [Member]
Warrants to purchase common stock					1,055,555		1,055,555
Warrant term					1 year		1 year
Exercise price per share					$ 0.70		$ 0.70
Common Stock [Member]
Number of shares issued for consulting services, shares							75,000
Number of shares issued for consulting services							$ 30,000
Stock Warrants [Member]
Stock based compensation expenses					$ 0	$ 43,105	$ 56,000	$ 91,297
Maximum [Member] | Stock Option [Member]
Exercise prices of stock options			$ 4.70
Maximum [Member] | Common Stock and Warrant Offering [Member] | Five-Year Immediately Vested [Member]
Exercise price per share					$ 1		$ 1
Minimum [Member] | Stock Option [Member]
Exercise prices of stock options			$ 1
Minimum [Member] | Common Stock and Warrant Offering [Member] | Five-Year Immediately Vested [Member]
Exercise price per share					$ 0.85		$ 0.85
Board of Directors [Member]
Reverse split, description			Effect a reverse split of the Company's common stock at a ratio of not less than 1-for-2 and not more than 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion.
Board of Directors [Member] | Subsequent Event [Member]
Reverse split, description	Effect a reverse split of the Company's common stock at a ratio of not less than 1-for-2 and not more than 1-for-100
Board of Directors [Member] | 2010 Equity Participation Plan [Member]
Common stock, shares authorized			20,000,000
Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized			150,000,000
Board of Directors [Member] | Maximum [Member] | Subsequent Event [Member]
Common stock, shares authorized	300,000,000

Stockholders' Deficiency - Sche

Stockholders' Deficiency - Schedule of Warrants Granted Assumptions (Details) - Warrant [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Contractual term (years)	5 years	5 years
Expected volatility	133.00%	139.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate	1.79%	2.73%	1.79%	1.92%
Contractual term (years)			1 year	1 year 11 months 23 days
Expected volatility			133.00%	128.00%
Maximum [Member]
Risk free interest rate	1.83%	2.83%	2.62%	2.83%
Contractual term (years)			5 years	5 years
Expected volatility			150.00%	139.00%

Stockholders' Deficiency - Sc_2

Stockholders' Deficiency - Schedule of Warrant Activity (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Number of Warrants Exercisable, Balance	3,532,455
Warrant [Member]
Number of Warrants Outstanding, Beginning Balance	3,483,403
Number of Warrants Outstanding, Issued	2,586,111
Number of Warrants Outstanding, Expired	(264,623)
Number of Warrants Outstanding, Ending Balance	5,804,891
Number of Warrants Exercisable, Balance	5,804,891
Weighted Average Exercise Price Outstanding, Beginning Balance | $ / shares	$ 3.63
Weighted Average Exercise Price Outstanding, Issued | $ / shares	0.77
Weighted Average Exercise Price Outstanding, Expired | $ / shares	5.41
Weighted Average Exercise Price Outstanding, Ending Balance | $ / shares	2.27
Weighted Average Exercise Price Exercisable, Balance | $ / shares	$ 2.27
Weighted Average Remaining Life In Years Outstanding	2 years 1 month 6 days
Weighted Average Remaining Life In Years Exercisable	2 years 1 month 6 days
Aggregate Intrinsic Value, Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Stockholders' Deficiency - Sc_3

Stockholders' Deficiency - Schedule of Stock Warrants (Details)	Sep. 30, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	5,804,891
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	5,804,891
Exercise Price One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,586,111
Warrants Exercisable, Weighted Average Remaining Life In Years	2 years 10 months 25 days
Warrants Exercisable, Exercisable Number of Warrants	2,586,111
Exercise Price One [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.45
Exercise Price One [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 0.99
Exercise Price Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	844,444
Warrants Exercisable, Weighted Average Remaining Life In Years	3 months 19 days
Warrants Exercisable, Exercisable Number of Warrants	844,444
Exercise Price Two [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 1
Exercise Price Two [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 1.99
Exercise Price Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	75,000
Warrants Exercisable, Weighted Average Remaining Life In Years	4 years 1 month 6 days
Warrants Exercisable, Exercisable Number of Warrants	75,000
Exercise Price Three [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2
Exercise Price Three [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.99
Exercise Price Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	70,000
Warrants Exercisable, Weighted Average Remaining Life In Years	3 years 9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	70,000
Exercise Price Four [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3
Exercise Price Four [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,965,457
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	1,965,457
Exercise Price Five [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Five [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	182,667
Warrants Exercisable, Weighted Average Remaining Life In Years	1 year 8 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	182,667
Exercise Price Six [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Six [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	40,000
Warrants Exercisable, Weighted Average Remaining Life In Years	9 months 18 days
Warrants Exercisable, Exercisable Number of Warrants	40,000
Exercise Price Seven [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Seven [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 7.99
Exercise Price Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	2,500
Warrants Exercisable, Weighted Average Remaining Life In Years	2 months 12 days
Warrants Exercisable, Exercisable Number of Warrants	2,500
Exercise Price Eight [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 8
Exercise Price Eight [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 9.99
Exercise Price Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	38,712
Warrants Exercisable, Weighted Average Remaining Life In Years	7 months 6 days
Warrants Exercisable, Exercisable Number of Warrants	38,712
Exercise Price Nine [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10
Exercise Price Nine [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 15

Stockholders' Deficiency - Sc_4

Stockholders' Deficiency - Schedule of Stock Option Granted Assumptions (Details) - Stock Option [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Risk free interest rate	1.47%	2.74%
Expected term (years)	10 years	5 years 4 days	10 years
Expected volatility	133.00%	139.00%
Expected dividends	0.00%	0.00%	0.00%	0.00%
Minimum [Member]
Risk free interest rate			1.47%	2.44%
Expected term (years)				5 years 4 days
Expected volatility			133.00%	129.00%
Maximum [Member]
Risk free interest rate			2.72%	2.74%
Expected term (years)				9 years 8 months 9 days
Expected volatility			140.00%	139.00%

Stockholders' Deficiency - Sc_5

Stockholders' Deficiency - Schedule of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2019USD ($)$ / sharesshares
Stockholders' Equity Note [Abstract]
Number of Options Outstanding Beginning | shares	4,703,785
Number of Options Granted | shares	245,000
Number of Options Forfeited | shares	(39,167)
Number of Options Outstanding Ending | shares	4,909,618
Number of Options Exercisable Ending | shares	3,532,455
Weighted Average Exercise Price Outstanding Beginning | $ / shares	$ 1.04
Weighted Average Exercise Price Granted | $ / shares	0.4
Weighted Average Exercise Price Forfeited | $ / shares	1.49
Weighted Average Exercise Price Outstanding Ending | $ / shares	1.01
Weighted Average Exercise Price Exercisable Ending | $ / shares	$ 1.11
Weighted Average Remaining Life In Years Outstanding Ending	7 years 4 months 24 days
Weighted Average Remaining Life In Years Exercisable Ending	6 years 8 months 12 days
Aggregate Intrinsic Value Outstanding Ending | $
Aggregate Intrinsic Value Exercisable Ending | $

Stockholders' Deficiency - Sc_6

Stockholders' Deficiency - Schedule of Stock Option by Exercise Price (Details)	9 Months Ended
	Sep. 30, 2019$ / sharesshares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Outstanding Number of Options	4,909,618
Options Exercisable, Weighted Average Remaining Life In Years	6 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	3,532,455
Exercise Price One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 0.26
Options Outstanding, Exercise Price, Upper | $ / shares	$ 0.74
Options Outstanding, Outstanding Number of Options	175,000
Options Exercisable, Weighted Average Remaining Life In Years	9 years 10 months 25 days
Options Exercisable, Exercisable Number of Options	175,000
Exercise Price Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 0.75
Options Outstanding, Exercise Price, Upper | $ / shares	$ 0.99
Options Outstanding, Outstanding Number of Options	4,623,367
Options Exercisable, Weighted Average Remaining Life In Years	6 years 8 months 12 days
Options Exercisable, Exercisable Number of Options	3,246,204
Exercise Price Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 1
Options Outstanding, Exercise Price, Upper | $ / shares	$ 5.99
Options Outstanding, Outstanding Number of Options	38,751
Options Exercisable, Weighted Average Remaining Life In Years	7 months 6 days
Options Exercisable, Exercisable Number of Options	38,751
Exercise Price Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 6
Options Outstanding, Exercise Price, Upper | $ / shares	$ 19.99
Options Outstanding, Outstanding Number of Options	37,500
Options Exercisable, Weighted Average Remaining Life In Years	4 years 3 months 19 days
Options Exercisable, Exercisable Number of Options	37,500
Exercise Price Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower | $ / shares	$ 20
Options Outstanding, Exercise Price, Upper | $ / shares	$ 30
Options Outstanding, Outstanding Number of Options	35,000
Options Exercisable, Weighted Average Remaining Life In Years	2 years 6 months
Options Exercisable, Exercisable Number of Options	35,000

Stockholders' Deficiency - Sc_7

Stockholders' Deficiency - Schedule of Stock Option Expense (Details) - Options [Member] - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock-based compensation expense	$ 234,045	$ (226,558)	$ 1,406,526	$ 1,435,249
Unrecognized expense	$ 1,016,917		1,016,917
Weighted Average Remaining Amortization Period	1 year 3 months 19 days
Consulting Expenses [Member]
Stock-based compensation expense	$ 34,021	163,757	505,669	669,574
Unrecognized expense	$ 147,392		147,392
Weighted Average Remaining Amortization Period	1 year 1 month 6 days
Research and Development Expense [Member]
Stock-based compensation expense	$ 106,085	98,148	352,017	242,586
Unrecognized expense	$ 329,604		329,604
Weighted Average Remaining Amortization Period	1 year 7 months 6 days
General and Administrative Expense [Member]
Stock-based compensation expense	$ 93,939	$ (488,463)	548,840	$ 523,089
Unrecognized expense	$ 539,921		$ 539,921
Weighted Average Remaining Amortization Period	1 year 1 month 6 days

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Extinguishment of derivative liabilities in connection with convertible note repayments, conversions and exchanges		$ 2,557,373
Reclassification of derivative liabilities to equity		2,809,565	$ 105,187
Gain on derivative liabilities		268,350
Warrants [Member]
Gain on derivative liabilities	$ 80,201	316,490
Fair value of derivative liabilities	48,166	48,166
Warrant [Member]
Derivative liabilities	1,059,889	1,059,889
Convertible Notes [Member]
Derivative liabilities	4,135,200	4,135,200
ECO [Member]
Derivative liabilities	1,142,942	1,142,942
Gain on derivative liabilities	$ 145,238	$ 584,840

Derivative Liabilities - Summar

Derivative Liabilities - Summary of Changes in Fair Value of Level 3 Derivative Liabilities (Details) - USD ($)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative liabilities, beginning balance	$ 1,094,607
Issuance of derivative liabilities	5,195,089
Extinguishment of derivative liabilities in connection with convertible note repayments and exchanges	(2,557,373)
Change in fair value of derivative liabilities	268,350
Reclassification of derivative liabilities to equity	(2,809,565)	$ (105,187)
Derivative liabilities, ending balance	$ 1,191,108

Derivative Liabilities - Summ_2

Derivative Liabilities - Summary of Derivative Liabilities Fair Value Assumption (Details) - Valuation Technique, Option Pricing Model [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Risk Free Interest Rate [Member] | Minimum [Member]
Derivatives, fair value measurement input, percentages	1.54%	1.93%	1.54%	1.22%
Risk Free Interest Rate [Member] | Maximum [Member]
Derivatives, fair value measurement input, percentages	2.16%	2.94%	2.62%	2.94%
Expected Term [Member] | Minimum [Member]
Derivatives, fair value measurement input, term	29 days	2 months 30 days	7 days	2 months 30 days
Expected Term [Member] | Maximum [Member]
Derivatives, fair value measurement input, term	5 years	5 years	5 years	5 years
Expected Volatility [Member] | Minimum [Member]
Derivatives, fair value measurement input, percentages	91.00%	120.00%	91.00%	100.00%
Expected Volatility [Member] | Maximum [Member]
Derivatives, fair value measurement input, percentages	133.00%	208.00%	156.00%	208.00%
Expected Dividend Rate [Member]
Derivatives, fair value measurement input, percentages	0.00%	0.00%	0.00%	0.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	Nov. 13, 2019shares	Nov. 14, 2019USD ($)$ / sharesshares	Mar. 31, 2019shares	Sep. 30, 2018USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019$ / sharesshares	Dec. 31, 2018shares
Common stock, shares authorized | shares						300,000,000	300,000,000
Warrant term						2 years 1 month 6 days
Warrants to purchase common stock | shares						5,804,891
Number of warrant outstanding | shares						5,804,891
Debt conversion, converted instrument, amount				$ 57,732	$ 110,636
Related Party Notes [Member]
Warrant term						5 years
Exercise price per share | $ / shares						$ 0.80
Conversion price | $ / shares						$ 0.60
Board of Directors [Member]
Reverse split, description			Effect a reverse split of the Company's common stock at a ratio of not less than 1-for-2 and not more than 1-for-20, with the Board of Directors having the discretion as to whether or not the reverse stock split is to be effected, and with the exact ratio of any reverse stock split to be set at a whole number within the above range as determined by the Board of Directors in its discretion.
Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized | shares			150,000,000
Subsequent Event [Member]
Increase in addtional common stocks shares | shares	300,000,000
Subsequent Event [Member] | Related Party Notes [Member]
Debt principal amount		$ 150,000
Interest rate		12.00%
Debt maturity period		Maturity dates ranging from April 2020 to May 2020
Debt instrument convertible conversion ratio		0.60
Repayments of convertible notes payable		$ 25,000
Accrued interest		$ 3,164
Subsequent Event [Member] | Convertible Notes One [Member]
Debt instrument convertible conversion ratio		0.58
Debt conversion, converted instrument, amount		$ 921,500
Subsequent Event [Member] | Convertible Notes Two [Member]
Debt instrument convertible conversion ratio		0.58
Debt conversion, converted instrument, amount		$ 55,000
Subsequent Event [Member] | Convertible Notes Three [Member]
Debt instrument convertible conversion ratio		0.58
Debt conversion, converted instrument, amount		$ 168,000
Subsequent Event [Member] | Common Stock and Warrant Offering [Member]
Number of shares issued | shares		3,333,333
Warrant term		5 years
Warrants to purchase common stock | shares		3,333,333
Exercise price per share | $ / shares		$ 0.20
Number of warrant outstanding | shares		2,111,111
Subsequent Event [Member] | Maximum [Member] | Convertible Notes Three [Member]
Conversion price | $ / shares		$ 1
Subsequent Event [Member] | Minimum [Member] | Convertible Notes Three [Member]
Conversion price | $ / shares		$ 0.25
Subsequent Event [Member] | Board of Directors [Member]
Reverse split, description		Effect a reverse split of the Company's common stock at a ratio of not less than 1-for-2 and not more than 1-for-100
Subsequent Event [Member] | Board of Directors [Member] | Maximum [Member]
Common stock, shares authorized | shares		300,000,000
Subsequent Event [Member] | Investor [Member] | Common Stock and Warrant Offering [Member]
Exercise price per share | $ / shares		$ 0.70
Aggregate gross proceeds of warrants		$ 500,000
Warrant expiration description		Expiration dates of such outstanding warrants from dates between February 2020 and May 2020 to new expiration dates between February 2024 and May 2024.
Subsequent Event [Member] | Investor [Member] | Maximum [Member] | Common Stock and Warrant Offering [Member]
Exercise price per share | $ / shares		$ 0.85
Subsequent Event [Member] | Investor [Member] | Minimum [Member] | Common Stock and Warrant Offering [Member]
Exercise price per share | $ / shares		$ 0.15
Subsequent Event [Member] | Lenders [Member] | Convertible Notes [Member]
Warrants to purchase common stock | shares		100,000
Debt principal amount		$ 1,144,500
Interest rate		12.00%
Debt maturity period		Maturity dates ranging from May 2020 to October 2020
Repayments of convertible notes payable		$ 1,275,000
Accrued interest		109,038
Proceeds from convertible promissory note		1,038,625
Debt discount amortized amount		$ 105,875
Percentage on prepayment premium		35.00%
Subsequent Event [Member] | Lenders [Member] | Convertible Notes One [Member]
Debt principal amount		$ 236,062
Accrued interest		$ 14,510
Convertible note converted into number of shares | shares		3,710,440
Subsequent Event [Member] | Lenders [Member] | Convertible Notes Two [Member]
Debt principal amount		$ 91,539
Debt maturity period		January 2020 to July 2020
Subsequent Event [Member] | Lenders [Member] | Other Notes [Member]
Debt principal amount		$ 175,000
Interest rate		15.00%
Debt maturity period		Original maturity date in November 2019
Subsequent Event [Member] | Lenders [Member] | Maximum [Member] | Convertible Notes One [Member]
Conversion price | $ / shares		$ 0.12
Subsequent Event [Member] | Lenders [Member] | Maximum [Member] | Convertible Notes Two [Member]
Conversion price | $ / shares		0.01
Subsequent Event [Member] | Lenders [Member] | Minimum [Member] | Convertible Notes One [Member]
Conversion price | $ / shares		0.05
Subsequent Event [Member] | Lenders [Member] | Minimum [Member] | Convertible Notes Two [Member]
Conversion price | $ / shares		$ 0.10